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CHAPTER I 
 
INTRODUCTION
1
 
 
Overview 
Nucleotide excision repair (NER) is multi-step, multi-protein process 
responsible for removing bulky lesions from the genome
1–3
.  In human NER, 
xeroderma pigmentosum complementation group A (XPA) and replication protein 
A (RPA) work together as scaffolds to organize damaged DNA and other repair 
proteins.  The importance of XPA in human NER is underscored by the 
observation that XPA mutations are frequently associated with severe clinical 
symptoms of the genetic disorder xeroderma pigmentosum (XP), including 
accelerated aging, increased rate of cancer and neurodegeneration
4–7
.  The 
interaction of XPA with DNA is a core function and a number of mutations in the 
DNA binding domain (DBD) are associated with XP disease
8
.  Although NMR 
structures of human XPA and complementary data on DNA binding have been 
available for many years, the molecular details of human XPA binding to DNA 
remain unclear.  In addition, one of the two interaction sites of XPA with RPA 
overlaps with XPA DBD and is also poorly characterized.  Structural and 
                                                          
1
 Part of this chapter was published in Sugitani, N., Sivley, R. M., Perry, K. P., Capra, J. A., 
Chazin, W. J., XPA: A Key Scaffold for Human Nucleotide Excision Repair, DNA Repair, 2016, 
44, 123-135.  Contents reused under permission by Elsevier (license #: 4063671121717). 
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biochemical tools have been employed to develop a model for the molecular basis 
of XPA-DNA and XPA-DNA-RPA interactions and the effects of disease-
associated mutations.  Findings from this study enhance the mechanistic 
understanding of human NER and XP disorders. 
 
Mechanisms of Nucleotide Excision Repair 
Our genome is constantly exposed to genotoxic agents such as UV-light, 
endogenous and exogenous reactive oxygen species, and chemical compounds 
from the environment.  These toxins give rise to a variety of DNA lesions ranging 
from single strand breaks, abasic sites, cross-links and covalent adducts.  If these 
lesions persist in the genome, the cells undergo either apoptosis or replication of 
the lesion-containing DNA that can result in mutagenesis, which in turn can lead 
to carcinogenesis.  Depending on the nature of the lesion, there are different types 
of repair pathways to eliminate DNA damage and combat genetic instability.  
Nucleotide excision repair (NER) is essential for removing bulky DNA lesions 
from the genome in both prokatyotes and eukatyotes
1,9
.  These lesions are 
typically generated from exposure to sun light and chemical carcinogens in the 
environment, as well as certain natural metabolites
10
.   
Defects in NER result in a spectrum of Xeroderma pigmentosum (XP) 
disorders
4–7
.  These maladies are characterized by extreme sensitivity to sunlight, 
which leads to sunburn, abnormal pigmentation, and significant increases in skin 
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cancer
46
.  The most severe cases of XP result in neurological degeneration, with 
loss of mental and sensory faculties
411–13
.  Currently there is no cure or therapy for 
XP disease; the average life expectancy of XP patients is ~30 years, although 
death in early adolescence is observed for the most severe cases.  Given the poor 
prognosis and dearth of options for XP patients, the development of new 
therapeutics remains a high priority.  Detailed mechanistic understanding of the 
NER process offers a pathway to the discovery of new therapeutic strategies for 
XP and XP-associated cancer.  XP disorders are caused by mutations in eight XP 
genes (XPA - XPG and XPV, also known as POLH) 
1,6,14,15
.  XPA – XPG genes 
encode for the proteins directly involved in NER pathway while XPV codes for 
the translesion polymerase η6. 
NER processing of damaged DNA in all organisms involves four distinct 
phases: 1) damage recognition, 2) NER bubble formation, 3) dual-incision of the 
damaged strand, and 4) gap-filling synthesis and ligation
1
 (Figure 1.1).  NER is 
effective at removing a wide variety of lesions because it (i) senses the presence 
of DNA damage without requiring damage-specific sensors
16
 and (ii) removes a 
lesion-containing DNA oligomer instead of removing the damaged base only, 
which otherwise would require specialized repair mechanisms for each type of 
lesion.  While considerable progress has been made in dissecting the mechanisms 
of NER in prokaryotes, detailed understanding of NER in eukaryotes has lagged 
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behind.  This lack of progress is due in large part to the inability to transfer the 
 
knowledge obtained for lower organisms as a result of the lack of conservation of 
the repair proteins
17,18
.  Human NER is more complicated than the simpler 
systems of lower organisms, requiring the coordinated action of over 30 proteins
18
.   
NER is divided into two sub-pathways: a specialized and faster pathway, 
transcription coupled repair (TCR), which removes lesions from actively 
transcribed genes; global genome repair (GGR) is responsible for NER of the rest 
of the genome
1,16,19–22
.  Figure 1.2 represents a working model of initiation steps 
 
Figure 1.1: DNA processing during NER. This schematic diagram shows 
DNA processing during NER. Bulky DNA lesion (red star) in DNA strand 
(black lines) needs to be recognized in step 1. In step 2, helicases unwinds 
duplex around the lesion. In the third step, nucleases (represented by 
scissors) excise the nucleotide containing the lesion. At the last step, 
resulting gap is filled by synthesizing healthy nucleotides complementary to 
the undamaged strand. 
5 
 
of 
 
Figure 1.2: A model for initiation steps of human GGR. In human 
GGR, most helix distorting lesions (red star) are sensed by the protein 
XPC (green). XPC recruits the TFIIH complex containing two helicases 
XPB and XPD that are responsible for unwinding the duplex around the 
lesion to create the NER bubble. Other NER factors including XPA, RPA, 
and XPG are believed to be recruited to the bubble and XPC is displaced.  
Together with RPA, XPA works as a scaffold to organize the formation 
and remodeling of the NER complex. This figure was prepared by a former 
graduate student Rachel C. Wright based on the information in reference 3. 
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human GGR
1,3,17
.  The main difference between TCR and GGR is at the initial 
step of recognizing the presence of damage.  In TCR, the presence of a bulky 
lesion is recognized by the stalling of RPA polymerase and subsequent 
recruitment of TCR specific CSA and CSB proteins, whereas in GGR, the damage 
sensor protein XPC with or without XPE is responsible for recognizing the 
presence of a bulky lesion
1,19
.  After recognition of the presence of damage, the 
transcription factor IIH (TFIIH) complex containing two helicases XPB and XPD 
is recruited to the damage site to unwind the duplex around the lesion
3,23,24
.  XPB 
unwinds dsDNA on the 5′ side of the lesion, which enables loading of XPD, 
which in turn unwinds about 20 nucleotides of duplex towards the lesion
24
.  It is 
generally accepted that XPD stalls when it encounters the lesion, creating the 
NER bubble structure
24
.  Thus, formally speaking, XPD is the damage recognition 
factor.  Once the NER bubble is formed, scaffolding proteins XPA and RPA are 
recruited to the bubble.  RPA is associated with the undamaged strand and XPA 
with the damaged strand and the adjacent junction
25,26
.  The 3′ nuclease XPG is 
also recruited as this time, which correlates with dissociation of XPC from the 
complex
3
.  This assembly of proteins around the bubble is termed the NER pre-
incision complex (Figure 1.2), and represents the formal commitment to NER.  
Without the correct formation of the NER complex, nucleases will not cut the 
lesion-containing nucleotide properly.  Once the pre-incision complex is formed, 
the 5′ nuclease XPF/ERCC1 is recruited27.  XPF cuts the nucleotide 5′ to the 
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lesion followed by 3′ incision by XPG, removing 24 – 30 nucleotides from the 
damage containing nucleotide (long)
27–29
.  The gap resulting from incision is filled 
by the replicative polymerase machinery, using the undamaged strand as 
template
30
. 
 
XPA 
The XPA gene was discovered in the 1970s in cell cultures derived from 
XP patients, along with other disease-associated XP genes (XPB – XPG, XPV) 31–
35
.  Since then, extensive efforts have been made to characterize the biochemical 
properties of XPA and understand its function in NER as well as the impact of 
specific disease-associated mutations.  XPA is involved in both TCR and GGR; 
the other proteins involved and their roles in these two sub-pathways are 
described elsewhere
3,16,20–30
.  In both pathways, XPA is recruited to the damage 
site by the TFIIH complex that is responsible for unwinding double-stranded 
DNA around the damaged nucleotide creating the NER bubble.  XPA is generally 
understood to function in damage-verification and assembly of NER incision 
complexes
2,36–38
.  XPA is recruited at the same time, and functions in coordination 
with, the eukaryotic ssDNA binding protein replication protein A (RPA).  
Together, they help recruit and properly position the excision nucleases.  RPA 
binds to the undamaged single strand, suggesting that XPA interacts with the 
damaged strand
25,26
.  However, XPA prefers to bind ss-dsDNA junctions and 
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duplexes with overhangs.  Although XPA has been studied for >20 years, several 
key questions remain about its function, including:  1) What is the structural basis 
of XPA interaction with protein binding partners and how does this lead to their 
positioning within the complex?  2) Is XPA involved in pathways other than 
NER?  3) How do different XPA mutations relate to NER outcomes and disease 
phenotypes?  The following sections highlight current knowledge of the 
interactions of human XPA with DNA, other NER proteins and proteins outside 
of NER, and the relationship between XPA mutants and XP disorders.   
 
XPA Structure and Interactions with DNA 
XPA structure 
XPA is a relatively small 273 residue protein that does not possess 
enzymatic activity but interacts with many other NER proteins, consistent with its 
role as a scaffold.  A domain map of XPA is shown in Figure 1.3.  XPA is 
organized around a central globular domain (XPA98-219).  3D structures of this 
domain were determined independently by two groups using solution NMR 
(PDB: 1XPA, 1D4U) (Figure 1.4)
39,40
.  XPA98-219 contains a C4 type zinc-finger 
motif
41
 in the N-terminal region and a shallow basic cleft in the C-terminal region 
(Figure 1.4).  The N- and C- termini of XPA are disordered and mediate a variety 
of protein interactions
42–48
.  Interestingly, severe XP symptoms associated with 
XPA mutations map primarily to the central domain
8
. 
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Figure 1.3:  Domain map of XPA and interaction partners. Schematic 
domain structure of human XPA protein (top).  The region containing the 
globular core is colored pink, with the location of the Zn finger indicated as a 
yellow circle.  The nuclear localization signal (NLS) is colored yellow.  The 
N- and C-termini are dynamically disordered. Known interaction partners are 
shown below the domain map, aligned with the XPA residues involved in 
each interaction.  Gray proteins are those known to interact with XPA but for 
which the sites of interaction have not been determined.  Blue indicates a 
binding partner for which the binding sites on XPA remain controversial. If 
known, the domain or residues involved in XPA binding are given in 
parenthesis.  
10 
 
  
Localization of XPA on the NER bubble 
XPA was shown to bind ssDNA-dsDNA junctions more strongly than 
ssDNA or duplex alone, suggesting that this protein is likely to be located at one 
end of the NER bubble rather than strictly associated with the damaged (or 
undamaged) single strand
37
.  Whether XPA binds to the junction 5′ or 3′ to the 
lesion remains unclear as evidence has accumulated supporting both models
49
.  
XPA is recruited to NER complexes via interactions of its flexible C-terminus 
with the p8 subunit of TFIIH (Figure 1.3)
50,51
.  However, it is difficult to model 
how XPA is positioned in the NER bubble based on XPA-TFIIH interactions 
alone due to the lack of knowledge of the orientation of p8within the TFIIH 
 
Figure 1.4:  A structure of the globular core of XPA.  Left - surface 
representation of the solution NMR structure of the globular core of XPA 
(PDB: 1XPA) colored by electrostatic field at the surface.  Positive charge 
is in blue tones and negative charge in red tones.  Right – Ribbon diagram 
of 1XPA. 
11 
 
complex.  The reported interaction of XPA with XPC suggests XPA localization 
at the 3′ junction as XPC binds to the duplex 3′ to the lesion.  This model is also 
supported by the interaction with RPA.  It is well established that RPA binds 
ssDNA in a 5′3′ orientation, which matches the direction of the undamaged 
strand in NER bubble
2
.  As noted below, XPA interacts with the tandem high 
affinity ssDNA binding domains RPA70AB, which are positioned 5′ on the 
undamaged strand (3′ to the lesion).  Support for the opposite model is based on 
XPA interactions with the 5′ incision nuclease XPF/ERCC1, assuming that in 
order to recruit and localize XPF/ERCC1 to the 5′ side of the lesion, XPA should 
also be located 5′ to the lesion.  In vitro studies using isolated XPA, RPA and 
damage containing DNA also support XPA localization 5′ of the lesion in both a 
duplex and a model bubble
26
.  In summary, although most models place XPA 5′ to 
the lesion, there is conflicting evidence and the controversy over the location of 
XPA within NER complexes is clearly not settled.  One critical issue that has not 
been considered is that these models are based on viewing the complexes as linear 
2-dimensional arrays.  In fact, consideration of the 3D topology of the NER 
bubble and proteins bound to it may allow XPA to be bound to DNA 3′ to the 
lesion yet still position XPF/ERCC1 to cleave 5′ of the lesion.  Clearly, there is a 
great need for determining the structure of functional NER complexes to truly 
understand where XPA is bound. 
 
12 
 
Structural analysis of XPA bound to damaged DNA 
The quest for structurally characterizing how XPA binds to the NER 
bubble started approximately twenty years ago.  Based on the combination of 
limited proteolysis and filter binding assays, the central globular region of the 
protein (residues 98-219) was proposed to serve as the DNA binding domain
41
.  
After determining the NMR solution structure, NMR chemical shift perturbations 
induced by a 9-nt ssDNA oligomer were used to map the DNA binding site onto 
the XPA98-219 structure and generate a model of the complex
52
.  This study 
suggested that the C-terminal basic cleft is the site of DNA binding.  However, 
because ssDNA is not a high affinity substrate, questions remain about the 
accuracy of this model for the interaction of XPA with the NER bubble
37
.  In fact, 
in 2014, we and others showed that in order to bind a junction DNA substrate as 
does the full-length protein, the globular XPA98-219 core must be extended C-
terminally by ~20 residues (see Chapter II)
53,54
.  
In 2015, Kisker, Carrell and co-workers reported X-ray crystal structures 
at 1.8-2.8 Å resolution for the S. cerevisiae XPA homolog Rad14 in complex with 
damage containing DNA (Figure 1.5)
55
.  These were the first high-resolution 3D 
structures of an XPA homolog in complex with DNA: one was with duplex DNA 
containing cisplatin that forms a 1,2-deoxydiguanosine intrastrand crosslink 
(PDB: 5A39) and the second was with the same duplex containing a N-
(deoxyguanosin-8-yl)-2-acetylaminofluorene (AAF) (PDB: 5A3D) adduct 
13 
 
 
(Figure 1.5).  Notably, the two structures are nearly identical except for the 
differences in the lesions, as reflected in the RMSD over all protein atoms of only 
0.22 Å.  The two key findings from the Rad14 structures are (i) two molecules of 
Rad14 bind to each side of the lesion-containing duplex, and (ii) the duplexes are 
kinked by 70º (Figure 1.5)
55
.  The interaction of Rad14 with the ss-dsDNA 
junction as observed in these structure is consistent with previous studies 
indicating that human XPA also preferentially binds to junction DNA
37
.  Also, 
Figure 1.5:  Structures of S. cerevisiae Rad14 in complex with DNA.  
A) Upper panel, x-ray crystal structure of Rad14t (dark and light green) 
bound to a cis-platin-containing duplex (PDB: 5A39).  Lower panel, 
sequence of the DNA duplex.  B) Upper panel, x-ray crystal structure of 
Rad14t molecules (purple and pink) bound to an AAF-containing duplex 
(PDB: 5A3D).  Lower panel, sequence of the DNA duplex.  X represents 
5-iododeoxyuridine. 
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these structures support the idea that XPA does not make direct contact with the 
lesion as suggested previously
3,56
.  It is interesting that Rad14 binds to both 
damaged duplexes as a dimer, consistent with a report that XPA forms a dimer
57
.  
Despite these in vitro observations, it is difficult to imagine how an XPA dimer 
can be fit and function within the context of multi-protein NER complexes 
processing the bubble.  
Comparisons of XPA and Rad14 can help assess if the Rad14 crystal 
structures adequately represent the interactions of human XPA with DNA in NER.  
Figure 1.6 shows a structure-guided alignment of XPA homologs from seven 
diverse species, and Figure 1.7 maps the evolutionary conservation of each 
position in XPA onto the 1XPA structure.  The human XPA and S. cerevisiae 
Rad14 constructs used for structural studies are also highlighted on the alignment.  
The Rad14 construct used for crystallization (Rad14188-302) has two insertions, one 
deletion, is four residues shorter at the N-terminus and four residues shorter at the 
C-terminus, and has 29% identity and 57% conservation to XPA98-219 (Figure 1.6).  
As noted above, XPA98-219 has severely reduced DNA-binding activity; a 20 
residue C-terminal extension is required to reproduce the DNA binding activity of 
FL XPA
53
.  It is therefore surprising that FL-XPA, FL-Rad14, and Rad14t bind 
duplex DNA containing cisplatin or AAF lesions very tightly
55
.  Moreover, Rad14 
does not bind to duplexes containing other commonly studied DNA lesions (e.g. 
(6-4)photoproduct ((6-4)PP), cyclobutane pyrimidine dimer 
15 
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(CPD)) with appreciable affinity
55
.  In light of these observations, it is of interest 
to know if XPA98-219 binds these substrates with comparable affinity.  
Figure 1.6:  Alignment of the XPA protein sequence across seven diverse 
species.  A structure-guided sequence alignment of XPA proteins from seven 
species.  The extent and secondary structure in human XPA98-219 construct as 
determined in the NMR structure (PDB: 1XPA) is structure are indicated 
with the dotted line above the sequence.  The secondary structure in the S. 
cerevisiae Rad14188-302 construct as determined in the crystal structures 
(PDB: 5A39, 5A3D) is given below the alignment.  The 20-residue extension 
of XPA required for full DNA binding is also highlighted.  Asterisks mark 
residues identified as critical indicated above the alignment.  The residues 
not visible in the for DNA binding in the Rad14 crystal structures.  The 
alignment was computed by PROMALS3D
133
 using 1XPA_A and 5A3D_A 
as guides.  Residues are colored and conserved alignment columns are boxed 
according to the default similarity scores in ESPript
134
.  
Figure 1.7:  Evolutionary conservation of XPA.  The surface 
representation of the globular core of human XPA (PDB: 1XPA) colored 
by evolutionary conservation computed from the alignment of 
orthologous XPA sequences from human, mouse, chicken, frog, fruit fly, 
fission yeast, and baker’s yeast (Figure 1.6).  The rendering of the 
structure was created with Chimera
135
.  
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Figure 1.8 compares the Rad14 structure with the solution NMR structure 
of XPA98-219.  Although the Rad14 construct is shorter, a larger number of C-
terminal residues were observed in the crystal structure.  Moreover, Rad14 has 
 
more helical character than XPA; this difference may be due to interaction with 
DNA or from the characteristics of the crystal lattice.  A β–hairpin at the N-
terminal zinc finger is observed in XPA but not in the yeast structure; this 
difference is likely due to the truncation of 4 residues at the N-terminus of the 
Rad14 construct.  Overall, the Rad14t and XPA98-219 structures are very similar 
(Figure 1.8-C); the only significant differences are minor shifts in the β–hairpin 
(between β2 and β3 in Rad14, which correspond to β4 and β5 in XPA) and the 
most C-terminal helix (α7 in Rad14, α3 in XPA).  The striking similarities 
between Rad14t and XPA98-219 structures imply that XPA will bind DNA in a 
Figure 1.8:  Comparing structures of human XPA with S. cerevisiae 
Rad14.  A) One molecule from the crystal structure of Rad14t bound to a cis-
platin-containing duplex (PDB: 5A3D).  B) A representative conformer from 
the NMR solution structure of the globular core of human XPA (PDB 
ID:1XPA).  C) Overlay of structures in panels A and B.  
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manner similar to Rad14 overall.  However, because these structures were 
determined with two very unique damaged duplexes, it is unclear if they 
adequately represent XPA interaction with DNA within NER complexes that 
process the full range of NER-repaired lesions. 
 
XPA-Protein Interactions  
The interaction of XP proteins with their binding partners was reviewed in 
2008
58
.  This section provides updated information and additional insights.  To 
provide an overview, the binding sites for various XPA binding partners are 
mapped on the XPA sequence in Figure 1.3. 
 
XPA binding partners in human NER 
XPA binds proteins involved in every step of NER, from damage 
recognition to gap-filling synthesis.  These proteins are introduced in the order of 
their recruitment to the site of damage.  
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XPC 
XPC is a 106 kDa protein responsible for detecting the presence of DNA 
damage in the GG-NER pathway
2
.  XPC functions as a heterotrimer with HR23B 
and centrin-2, which stimulate XPC DNA binding activity and increases cellular 
stability
59
.  Once engaged on the damaged duplex, XPC recruits the TFIIH 
complex
51
.  As discussed in the TFIIH section below, XPA is recruited to the 
damaged site after formation of the NER bubble through an interaction with 
TFIIH.  However, XPC also binds XPA; using a pull-down assay, Bunick et al. 
showed that XPA pulls down XPC1-492 and XPC154-334, suggesting that N-terminal 
residues 154-334 are responsible for binding to XPA
60
.  There is currently no 
structure of the complex of XPA and XPC or more detailed mapping of XPC 
interaction sites on XPA sequence.  So the functional role of this interaction has 
yet to be established. In particular, one would like to know if XPA-XPC 
interaction is responsible for the recruitment of XPA to the damaged site or 
guiding XPA to a certain site on the NER bubble?  XPA (and RPA) was 
originally thought to contribute to damage recognition and verification, in part 
due to its interaction with XPC.  However, more recent experiments showed that 
XPA (in concert with RPA) is recruited to the damaged site after the formation of 
the NER bubble
51
.   
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XPE  
Damaged DNA-binding protein 2 (DDB2), also named XPE, is another 
protein involved in damage recognition in GG-NER.  XPE exists as heterodimer 
with DDB1
61
, and together they recognize a wide variety of lesions
62
.  Mutations 
in XPE often result in mild XP disorders
62
.  Although the DDB1/2 complex is 
dispensable for NER reconstituted in vitro, it enhances this activity especially for 
CPD lesions
62
.  The DDB1/2 complex binds to CPD-containing duplexes and 
creates a kink in the DNA that is recognized by XPC; XPC alone does not directly 
bind to DNA containing this lesion
63,64
.  Wakasugi et al. showed that XPA 
interacts with the DDB2 (XPE) subunit of the XPE/DDB1 dimer and that this 
interaction is mediated by XPA residues 185–226 48.  They also showed that XPA 
R207G mutation diminishes XPA-XPE binding, prevents XPA recruitment to the 
NER bubble, and fails to stimulate CPD removal by NER 
48
.  In other studies, 
R207 was reported to be involved in DNA binding
65
, and the R207Q mutation 
was discovered in cancer patients (Table 1.1).  It is generally accepted that XPA is 
primarily recruited to the repair site by the TFIIH (see below), so XPA interaction 
with damage recognition proteins such as XPC and XPE presumably functions to 
position XPA to specific positions within NER complexes, although the details 
are yet to be elucidated.  
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Table 1.1: Disease associated mutations in XPA 
 
Mutation in 
gene 
Mutation in 
protein 
Mutation type Disease 
phenotype 
Possible Effects 
on XPA Function 
Source 
171+2T>G NA splice site XP-A; 
severe 
Disrupts 5′ splice 
donor site of intron 
1 
Tanioka et al.
136
  
268_269insA
A 
variant1: 
V9EfsX15, 
variant2: 
V9EfsX6 P96-
Q185del 
insertion/ 
frameshift 
XP-A; 
severe form 
 Lehmann et al.
137
 
 
281C>T P94L missense Severe XP; 
neurologica
l disease or 
disruption 
of function 
 Cleaver and 
States
13
 
 
323G>T C108F missense XP-A; 
severe form 
zinc finger 
disruption 
Satokata et al./ 
States et al.
8,138
 
 
331G>T E111X nonsense XP-A; 
severe form 
 Amr et al./ 
Messaoud et 
al.
139,140
  
 
348T>A Y116X nonsense Severe XP 
neurologica
l disease or 
disruption 
of function 
 Cleaver and 
States
13
 
 
349_353 
delCTTAT 
L117EfsX4 deletion/ 
frameshift 
XP-A; 
severe form 
 
Ghafouri-Fard et 
al.
141
 
 
374delC T125IfsX15 deletion/ 
frameshift 
XP-A; 
severe form 
 Amr et al.
139
 
 
377C>T C126T missense XP-A  States et al.
8
 
387-1G>A NA splice site XP-A Disrupts 5′ splice 
donor site of intron 
3 
Satokata et al.
138
  
388-12A>G NA splice site XP-A Disrupts 3′ splice 
acceptor site of 
intron 3 
States et al.
8
 
388-2A>G NA splice site XP-A Disrupts 3′ splice 
acceptor site of 
intron 3 
Satokata et al. 
142
 
388-1G>C NA splice site XP-A; 
severe form 
Disrupts 3′ splice 
acceptor site of 
intron 3 
Tanaka et al. 
108
 
388-1G>T NA splice site XP-A Disrupts 3′ splice 
acceptor site of 
intron 3 
States and 
Myrand
143
 
545_546insT
A 
L182Ffs insertion/ 
frameshift 
XP-A  ClinVar 
553C>T Q185X nonsense XP-A; 
severe form 
 cBio 
555G>C,T Q185H missense XP-A  cBio 
555-1G>C NA splice site XP-A Disrupts 5′ splice 
donor site of intron 
Satokata et al. 
138
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4 
555+8A>G NA splice site XP-A Disrupts 5′ splice 
donor site of intron 
4 
Sidwell et al.
144
 
619C>T R207X nonsense XP-A, 
neurologica
l 
impairment 
and mild 
skin 
abnormality 
 Santiago et 
al./Messaoud et 
al.
140,145
 
 
620G>A R207Q missense  inhibition of XPE 
binding  
Wakasugi et al.
48
 
 
622C>T Q208X nonsense XP-A  
Maeda et al.
146
 
631C>T R211X nonsense Severe XP 
neurologica
l disease or 
disruption 
of function 
 Cleaver and 
States
13
 
 
647_648delA
G 
K217EfsX3 deletion/ 
frameshift 
XP-A; 
severe form 
 Sun et al.
147
 
 
672-1G>C NA splice site XP-A Disrupts 5′ splice 
donor site of intron 
5 
Sato et al.
148
 
682C>T R228X nonsense Mild XP 
neurologica
l disease or 
partial 
function 
 Cleaver and 
States
13
 
 
683G>A R228G missense Improved 
Adduct 
Removal 
 Porter et al.
149
 
690insT R231KfsX15 insertion/ 
frameshift 
XP-A; mild 
form 
 Takahashi et al.
111
 
 
700G>T V234L missense Improved 
Adduct 
Removal 
 Porter et al.
149
 
731A>G H244R missense XP-A; mild 
form 
 Satokata et al.
138
 
 
779_780 
insTT, 
780_781 
insTT 
T260IfsX9 insertion/ 
frameshift 
XP-A; mild 
form 
 Takahashi et al.
111
 
 
 
 
TFIIH  
The TFIIH complex is composed of 10 subunits that are independently 
folded proteins capable of forming a range of sub-assemblies and other complexes.  
These subunits are divided in three groups: the cyclin-activated kinase (CAK) 
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domain, the core domain, and XPD.  The CAK domain is composed of CDK7, 
cyclin H, and MAT1.  The core domain comprises p44, p34, p62, p52, 
trichothiodystrophy A (TTDA, also termed p8) and XPB.  XPD plays a key role 
in linking the CAK and core domains.  High resolution structures of domains and 
subdomains, as well as an EM structure of human TFIIH have been reported
66–78
.  
TFIIH is recruited to the damage site by interacting with XPC through its p62 and 
XPB domain
42,75,79
.  The two NER helicases, XPB and XPD, are responsible for 
opening of the damaged DNA duplex and creating the NER bubble
24
.  A recent 
study revealed that the helicase activity of TFIIH is inhibited by the presence of 
bulky lesions and that unwinding is XPC dependent
38
.  
Although XPA preferentially binds to ss-ds junction DNA, it is generally 
accepted that it is first recruited to the NER bubble through an interaction with 
TFIIH
44
.  XPA was also shown to enhance the helicase activity of TFIIH, but only 
in the absence of bulky lesions, apparently to provide further damage verification 
during NER
38
.  XPA interacts with both p8 subunit of TFIIH
50,51
.  XPA was 
reported to mediate the dissociation of CAK domain from TFIIH, which then 
promotes incision of damage-containing nucleotide
80
.  Interestingly, XPA was 
also reported to interact with another transcription factor TFIIE
81
.  However, the 
physiological role of this interaction has yet to be established.  
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RPA  
RPA is the primary eukaryotic ssDNA binding protein required for 
virtually all DNA transactions82–85.  In NER, RPA functions together with XPA to 
scaffold the assembly and stabilize NER complexes.  The primary function of 
RPA is to bind and protect the undamaged strand in the NER bubble
82,83,86
.  RPA 
also plays an important role in the transition between dual incision and the re-
synthesis phase of NER
3,51
. 
Two contact points with XPA have been reported.  The primary 
interaction involves the RPA32C protein recruitment domain and XPA residues 
29-46
46
.  A secondary weaker interaction occurs between RPA70AB and the 
XPA98-219 , but the specific site has not yet determined
45,87,88
 (Figure 1.3).  Figure 
1.9 shows the XPA-binding domains within RPA, as well as a model for XPA-
RPA32C complex.  There are two hypotheses for the RPA70AB binding site in 
XPA.  NMR titration of XPA98-219 with RPA70 constructs suggested the N-
terminus of XPA98-219  containing the zinc finger is involved
39,45
.  Biochemical 
pull-down and cell-free NER assays with XPA mutants concluded that C-terminus 
of XPA98-219 is responsible for the interaction
89,90
.  In the latter model, XPA 
residues responsible for RPA70AB and DNA interaction may overlap.  A 
biochemical study to test how each RPA70AB-binding residue within XPA98-219 
affects DNA binding and NER activity concluded that K141 and K179 are 
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involved in RPA70 interaction but not binding DNA; mutation of these residues 
decreases damage incision efficiency
90
.  They also demonstrated that disruption of  
 
Figure 1.9:  Structures of XPA in complex with other NER proteins.  A) 
Schematic domain map of human RPA.  DNA binding domains (A, B, C, D) have 
stipled shading.  Domains involved in protein interactions are underlined, with 
those involved in XPA interactions in pink.  B) Ribbon diagram of the solution 
NMR structure (PDB: 1DPU) of RPA32C (light green) in complex with a peptide 
fragment of UNG2 (salmon), which binds to RPA32C in the same manner as 
XPA29-46.  C) X-ray crystal structure of a peptide fragment of XPA (salmon) in 
complex with ERCC1 (violet) (PDB: 2JNW).  XPA residue numbers are indicated 
in panels B and C. 
 
both RPA32C and RPA70AB interactions severely lowered NER activity, 
supporting the hypothesis that both contacts are critical for NER function
90
.  In 
 
26 
 
contrast, lysine scanning mutagenesis revealed K141 and K179 are involved in 
DNA binding
65
.  The inconsistency in DNA binding results from these studies are 
likely due to differences in the approaches to characterize the interaction (filter 
binding assay versus EMSA, different DNA substrates)
65,90
.  A high-resolution 
structure of an XPA98-219 -DNA-RPA70AB complex would be extremely useful to 
clarify how XPA simultaneously engages DNA and protein binding partners.  
Interestingly, an NMR study revealed that the ssDNA and XPA binding sites on 
RPA70AB overlap
88
.  This competition may play a role in how substrates are 
handled and processed.  Further investigation is required to map RPA70AB and 
DNA binding sites on XPA with greater specificity. 
 
XPF/ERCC1 
XPF is the structure-specific endonuclease responsible for incision 5′ to 
the lesion.  XPF functions as a heterodimer with ERCC1.  XPF/ERCC1 is 
recruited to the NER bubble by an interaction between ERCC192-119 and XPA96-
114
43
.  An X-ray crystal structure of the ERCC1-XPA96-114 complex is available
27
 
(Figure 1.9-C).  The ability of XPF/ERCC1 to bind DNA and XPA 
simultaneously has been investigated, but there remains some debate as to how 
XPA is positioned in the NER bubble relative to the 5′ XPF/ERCC1 cleavage 
site
49
. 
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PCNA  
Proliferating cell nuclear antigen (PCNA) is an essential protein for 
multiple DNA processing pathways
91
.  In NER, PCNA appears at the gap-filling 
synthesis phase to facilitate replication of the incised nucleotide using the 
undamaged strand as the template.  It is widely accepted that all proteins in the 
NER incision complex, except for RPA, are displaced between the incision and 
gap-filling synthesis phases.  However, XPA contains a PCNA binding APIM 
(AlkB homolog 2 PCNA interacting motif) sequence, and it has been shown that 
XPA and PCNA co-localize to damaged DNA foci in cell culture
92
.  This finding 
opens up a new set of mysteries:  1) Is XPA needed for gap-filling synthesis?  2) 
Is the XPA-PCNA interaction essential for the NER function?  3) If not, is this 
interaction required for DNA processing pathways other than NER? 
 
XPA binding partners not directly involved in NER 
Besides the proteins directly involved in NER, XPA is also known to 
interact with proteins involved in the regulation of NER, including ATR and 
PARP-1.  Moreover, while XPA is most well recognized for its function in NER, 
there are also additional proteins interacting with XPA that are neither established 
as a part of NER nor known to be involved in the regulation of NER. 
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ATR  
The serine/threonine protein kinase ATR (ataxia telangiectasia and Rad3-
related, also known as FRP1 (FPAP-related protein 1)) is a central protein in the 
DNA damage response.  ATR is known to be capable of regulating NER.  In 
particular, ATR phosphorylation of Ser196 in XPA enhances nuclear import of 
XPA so that it can be localized to the sites of damage
93
.  Proteomic mass 
spectrometry analysis showed that this interaction is mediated within the globular 
XPA98-219
94
.  A recent study also showed that XPA phosphorylation by ATR 
enhances XPA stability by inhibiting ubiquitination by the E3 ubiquitin ligase 
HERC2 and subsequent degradation
95
. 
 
PARP-1 
Poly(ADP-ribosyl)ation (PARylation) is an increasingly recognized post-
transcriptional protein modification.  PARylation by PARP-1 (PAR polymesase-
1) is reported to be involved in the repair of DNA single and double strand breaks, 
as well as in NER
96–100
.  XPA was found to be PARylated, with the critical region 
mapped to C-terminal residues 213–237 that contain a conserved PAR binding 
motif
101
.  Interestingly, while XPA stimulates PARP-1 activity, PARylation of 
XPA was shown to reduce DNA binding activity of XPA
101
.  Cell based imaging 
experiments showed that PARP inhibition results in the impairment of XPA 
localization to sites of DNA damage, suggesting that PARylation of XPA may 
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play a role in formation of the PIC
101
.  It is interesting to note that XPC also 
seems to be PARylated
102
. 
 
Additional XPA binding proteins 
An XPA yeast two-hybrid screen identified an additional set of five XPA 
binding (XAB) proteins not previously known as binding partners.  The validity 
of the approach was supported by the detection of several previously identified 
XPA binding partners such as RPA and ERCC1
103
.  Among the XAB proteins, 
XAB3, XAB4 and XAB5 were known proteins or closely related to known 
proteins: XAB3 is the metallopeptidase PRSM1, XAB5 is the Golgi reassembly 
stacking protein GRASP65, and XAB4 contained a region homologous to 
XAB5
103
.  The role of these XPA interactions in NER, or if these interactions 
suggest involvement of XPA in other pathways, is currently unclear.  
XAB1 and 2 were novel proteins.  XAB1 is a GTPase that interacts with 
residues 30–34 of XPA103 and contains a nuclear localization signal (NLS)104, 
which suggests that it facilitates the nuclear localization of XPA.  However, ATR 
has been shown to play an important role in XPA nuclear localization, so further 
investigation is needed to determine if both are required and to clarify the 
biological significance of the XPA-XAB1 interaction.  XAB2 is an essential 
protein in mice as the disruption of the XAB2 gene resulted in embryonic 
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lethality
105
.  XAB2 contains 15 TPR (tetratricopeptide repeat) motifs and appears 
to have a role in TCR and transcription
106
.  In addition to XPA, it also interacts 
with other proteins involved in TCR such as CSA, CSB, and RNA polymerase 
II
106
.  The exact role of XPA-XAB2 interactions in NER remains to be 
investigated. 
 
XPA Mutations and Disease 
Many XPA mutations are associated with XP; however, the severity of the 
symptoms vary dramatically depending on the mutation
8
.  Some XPA mutations 
do not produce noticeable defects or only result in mild skin abnormalities, while 
others give rise to more severe symptoms, including progressive neurological 
degeneration and skin cancer.  The differences in clinical outcomes are presumed 
to arise from partial versus complete inactivation of XPA, although the precise 
mechanisms remain unclear
4,12,13,107
.  However, it is well established that 
complete deletion of XPA results in very severe disease.  To characterize the 
current understanding of how XPA mutations affect disease phenotype, we 
catalogued all known disease-causing XPA mutations and their biochemical 
effects, as well as patterns of non-disease-associated germline and somatic 
variation in XPA (Table 1.1). 
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The mRNA coding for XPA protein is composed of 6 exons (Figure 
1.10)
108,109
.  Severe XP symptoms are correlated with mutations resulting in little 
to no production of functional XPA protein, e.g., severe truncations and 
disruptions of the zinc finger
8,13,110
.  Deletion of exon 1 (coding for N-terminal 
residues including the RPA32Cand ERCC1 binding regions as well as the NLS, 
Figure 1.3) was previously reported to be dispensable for NER activity and 
deletion of exon 6 (coding for C-terminal residues including the TFIIH binding 
region, Figure 1.3) result in marginal NER disruption
109
.  This is supported by a 
clinical report of two C-terminal truncation mutations that result in unusually mild 
XP-A symptoms
111
.  Furthermore, there are no characterized mutations in exon 1 
associated with severe XP (Table 1.1).  Deletion of any of the remaining exons (2-
5), which code for the DNA binding domain, resulted in complete loss of NER 
activity.  Biochemical studies have also shown that mutation of any of the four 
cysteines coordinating the zinc finger results in unfolded protein
110
.  These results 
led to the conclusion that the XPA-DNA interaction is critical for NER activity.  
However, as shown in Figure 1.3, these exons also code for regions important for 
interactions with target proteins including the DDB1/2 complex, RPA, and PCNA, 
as well as sites for post-translational modification.  In addition, many variants that 
influence splice donor and acceptor sites, particularly in intron 3, have been 
associated with XP-A (Table 1.1, Figure 1.10). 
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Figure 1.10:  XPA gene structure and mutations.  The blue boxes give a 
schematic representation of the human XPA gene structure.  Exons are 
represented by large boxes, introns by medium boxes, and introns by blue lines 
connecting the exons.  Colored ellipses within the gene model show the location 
and frequency of XPA mutations observed in the ExAC database of 60,706 
human exome sequences.  Missense mutations and inframe indels are colored 
yellow; frameshifts, gained stop codons, and mutations to splice acceptor/donor 
sites are colored red; synonymous mutations are in green; and non-coding variants 
are colored black.  The eccentricity of each ellipse indicates the mutation’s 
frequency in the ExAC population.  Coding variation is rare in XPA; the most 
common coding variant has a frequency of 0.3%. 
 
Analyzing the frequency and patterns of germline genetic variation in 
XPA within relatively healthy individuals unaffected by severe XP illustrated the 
strength of selection on XPA and highlighted regions tolerant of mutation.  We 
identified all missense, loss-of-function (LOF), and intronic variants observed in 
whole exome sequences from 60,706 unrelated individuals of diverse genetic 
ancestries from the Exome Aggregation Consortium (ExAC) (Figure 1.10).  The 
ExAC is a multiple-cohort dataset that combines whole-exome sequencing data 
from several projects to provide a dense catalog of variant locations and 
frequencies across global populations.  XPA is devoid of common protein-coding 
variation; the most common missense or LOF variant is at a frequency of 0.3%.  
This indicates considerable negative selection on the coding sequence.  
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Considering all rare variation in the analysis, XPA contains fewer missense and 
LOF variants than expected based on mutation patterns across all genes (95 sites 
versus 109).  Exon 6 exhibits the highest density of variation with missense or 
LOF variants at ~21% of its translated nucleotides.  This is consistent with the 
marginal functional disruption observed with its deletion described earlier.  
XP patients have dramatically increased risk for early development of skin 
cancers, including basal cell carcinomas and malignant melanomas, presumably 
due to defects in their ability to repair UV induced DNA damage.  To assess 
whether somatic mutations in XPA are also associated with cancer development, 
we identified 56 somatic mutations in XPA in 121 cancer studies from the cBio
112
 
Portal for Cancer Genomics.  No mutation was observed in more than three 
samples; this low recurrence rate suggests that somatic mutations in XPA are not 
themselves significant drivers of cancer in general; however, additional studies 
focused on skin cancers are needed.  
Taken together, these observations suggest considerable constraint on the 
protein sequence of XPA; however, many rare mutations are observed in XPA in 
individuals without XP.  Mutations that result in misfolding or severe truncation 
of XPA often lead to severe XP.  Disruption of XPA-DNA interactions may not 
be sufficient to completely disturb NER and produce severe XP symptoms.  It 
remains to be determined how disruptions of XPA’s protein interactions relate to 
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XP severity.  Understanding the mechanisms by which each mutation affects the 
protein, which aspects of NER are affected, and the relationship to disease 
symptoms will require additional genetic and structural analysis of families and 
individuals with XP. 
 
Experimental Overview 
 Investigation of XPA interactions with other macromolecules such as 
DNA and RPA would not have been possible without the integration of structural 
and biophysical tools.  This section provides a brief overview of the concepts for 
the key experimental methods employed in this study.   
 
Nuclear magnetic resonance (NMR) spectroscopy 
 NMR spectroscopy provides information on the structure, dynamics, and 
interactions of biomolecules.  The NMR phenomenon is based on the induction of 
resonance in NMR-active atomic nuclei, which can be detected as characteristic 
frequencies as the system returns to equilibrium
113–117
.  The NMR chemical shift 
parameter (the characteristic frequency) is highly sensitive to the surrounding 
chemical environment and this provides a valuable tool for determining structures 
and characterizing interactions.  Information on dynamics can be obtained 
35 
 
because the decay of the NMR signal back to equilibrium is highly sensitive to 
molecular motions.  NMR spectroscopy can be performed in the solid state NMR 
or in solution.  In this work, all NMR experiments employed the solution NMR 
approach. 
Although NMR spectroscopy can be applied to a variety of molecules, this 
section will focus on its application for proteins as this dissertation focuses on the 
characterization of XPA protein.  The most basic 1D NMR spectrum provides 
valuable insights into protein structure and can be used for example to assay 
tertiary structure and for monitoring the progress of titrations.  However, 1D for 
proteins is limited because proteins and nucleic acids have so many nuclei that 
their 
1
H 1D NMR spectra are extensively overlapped.  Higher order hetero-
nuclear 2D (e.g. correlation between 
1
H and 
15
N or 
1
H and 
13
C) or 3D (correlation 
between 
1
H, 
15
N and 
13
C) NMR experiments resolve the overlap problem by 
dispersing overlap resonances in the extra dimension(s).  Isotopic enrichment is 
required for nearly all heteronuclear studies.  Although the 
1
H isotope is found in 
high natural abundance in macromolecules, this is not the case for the key 
15
N and 
13
C nuclei.  In order to incorporate these isotopes, proteins are usually 
recombinantly expressed in bacteria grown in minimal media supplemented with 
15
N-ammonium chloride or 
13
C-glucose as sole nitrogen and/or carbon sources
118
. 
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 Assigning the resonances to specific nuclei in the molecule is an essential 
step for any in-depth NMR analysis.  The assignment process requires acquisition 
of a series of complementary experiments. 
While there are many different types of 2D NMR experiments, this 
dissertation project employed 
15
N-
1
H heteronuclear single quantum coherence 
(HSQC) experiment, a key tool for structural analysis of proteins
119
.  
15
N-
1
H 
HSQC is often described as ‘finger print of a protein’.  The NMR spectrum from 
this experiment gives the chemical shift for each correlated 
15
N-
1
H pair as a single 
peak in the 2D plane; in other words, each chemical shift represents each amino 
acid in the protein backbone, except for proline.  HSQC informs several important 
properties of proteins.  Predictions of folding as well as secondary and tertiary 
structure of the protein can be obtained by observing the dispersion of the 
chemical shifts.  A series of 3D NMR experiments allows for assignment of the 
spectra, or identifying which chemical shift corresponds to which amino acid in 
the protein
120,121
.  As mentioned above, positions of each chemical shift in the 
HSQC spectrum depends on the chemical environment of each nuclear spin.  
Therefore, as long as assignments are available, HSQC can also reveal which 
amino acids are involved in interaction with other molecules because only 
chemical shifts experiencing the chemical environment change (for example, by 
interaction with other molecules) will change in its intensity or position in the 
spectrum
122
. 
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 While HSQC is a powerful tool for characterizing proteins, it is limited to 
proteins smaller than ~35 kDa.  Larger molecules tumble slowly in solution, 
resulting in faster (shorter) transverse relaxation times (T2).  This leads to 
broadening of chemical shift and poses difficulty detecting those peaks.  
Development of transverse relaxation optimized spectroscopy (TROSY) allowed 
for the basic heteronuclear correlation experiments to be expanded to proteins or 
complexes up to ~ 100 kDa
123
.  TROSY cancels different physical processes that 
dictate relaxation rates to attenuate T2 relaxation, resulting in single, sharp 
chemical shift in the NMR spectrum
123
.   
 
Fluorescence anisotropy (FA) binding assay 
 Fluorescence anisotropy (FA) is an approach to measure the binding of a 
ligand to a fluorescently tagged molecule and can be used in a high-throughput 
mode for quantifying interactions
124
.  The application of the FA assay to measure 
protein-nucleic acids interactions is well established
125–127
.  In this project, FA 
assay was exclusively used to screen binding of XPA constructs to various 
fluorescently labeled DNA substrates.  When the fluorophore attached to DNA is 
excited, it exhibits fluorescence anisotropy, or the phenomenon where the light 
emitted by the fluorophore shows different intensities along parallel (I‖) and 
38 
 
perpendicular (Iꓕ) axes of polarization.  Fluorescence anisotropy (r) is defined as 
the ratio of the polarized component to the total intensity (IT): r = (I‖ - Iꓕ)/ IT. 
As a protein binds to the labeled DNA, fluorescence anisotropy of the 
fluorophore changes, partially due to the change in size of the molecule to slow 
tumbling in solution.  FA assay monitors this change in fluorescence anisotropy 
as increasing amount of protein is added to the labeled DNA.  The FA assay is 
typically set up in a 384-well plate where each column of the plate contains one 
titration and fluorescence anisotropy of each well is read by a plate reader.  This 
allows for high-throughput, collecting eight distinct reactions with each having 
triplicates in one experimental run.  The plate based assay is also economical as it 
only requires very small amounts of purified components at relatively low 
concentrations (nm – µm range).         
 
Microscale thermophoresis 
 Microscale thermophoresis (MST) is a powerful tool to quantify 
interactions between biomolecules
128
.  MST depends on the thermophoresis 
phenomenon whereby molecules move along a temperature gradient with distinct 
properties
129
.  When a protein is in a solution at a certain temperature, molecules 
are distributed homogeneously.  If the temperature gradient is induced in the 
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solution, molecules exhibit positive or negative thermophoresis (movement of 
molecules from warm to cold or cold to warm temperatures, respectively)
129
.  In 
MST experiments, change in thermophoresis is detected by monitoring the 
movement of fluorescently labeled molecule as the temperature gradient is 
induced by local exposure to an infrared laser.  In the case of the experiments 
performed for this thesis work, the DNA molecules were fluorescently labeled.  
The protocol involves labeled molecules at a known concentration being titrated 
with unlabeled binding partner in glass capillaries.  The rate of thermophoresis 
depends on various factors including the size of the molecule.  Therefore, 
fluorescently labeled DNA mixed with different concentrations of XPA proteins 
exhibit distinct thermophoresis from those not interacting with XPA.  This 
difference in thermophoresis at each point of titration can be fit to a binding curve 
to quantify the interaction
128
.  While MST requires more reagents and time 
compared to FA assay, it is still a relatively economical and quick assay: a 
titration takes about 15 minutes.  The main advantage of MST over the FA assay 
is the ease of troubleshooting.  Since it is a specialized method for assaying 
binding, NanoTemper, Inc. has established a case-by-case troubleshooting 
protocol, three types of capillaries to accommodate various samples, as well as the 
support system by the technology specialists for their Monolith instruments. 
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Circular dichroism 
 Light can be either linearly or circularly polarized.  Circular dichroism 
(CD) is the phenomenon whereby right and left circularly polarized light are 
absorbed unequally
130
.  CD can be represented in absorption bands of any 
optically active molecule and it reflects secondary structures of these molecules.  
Therefore, in biochemistry, CD is most often applied to study the secondary 
structures as well as folding of macromolecules
131,132
.  In this project, CD was 
applied to compare the thermostabilities of mutant XPA DBD to WT using CD 
thermodenaturation.  Since the CD spectra represent secondary structures of the 
protein, it can also represent distinct folded and unfolded states of the protein.  
CD thermodenaturation monitors CD spectra at of a protein at a set wavelength as 
the temperature increases to capture the loss in secondary structure as the protein 
unfolds.             
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CHAPTER II 
 
RE-DEFINING THE DNA-BINDING DOMAIN OF HUMAN XPA
2
 
 
Abstract 
Xeroderma pigmentosum complementation group A (XPA) protein plays a 
critical role in the repair of DNA damage via the nucleotide excision repair (NER) 
pathway. XPA serves as a scaffold for NER, interacting with several other NER 
proteins as well as the DNA substrate. The critical importance of XPA is 
underscored by its association with the most severe clinical phenotypes of the 
genetic disorder Xeroderma pigmentosum. Many of these disease-associated 
mutations map to the XPA98-219 DNA-binding domain (DBD) first reported ~20 
years ago. Although multiple solution NMR structures of XPA98-219 have been 
determined, the molecular basis for the interaction of this domain with DNA is 
only poorly characterized. In this report, we demonstrate using a fluorescence 
anisotropy (FA) DNA-binding assay that the previously reported XPA DBD binds 
DNA with substantially weaker affinity than the full-length protein. In-depth 
analysis of the XPA sequence suggested that the original DBD construct lacks 
critical basic charge and helical elements at its C-terminus. Generation and 
analysis of a series of C-terminal extensions beyond residue 219 yielded a stable, 
                                                          
2
 This work was published in Sugitani, N., Shell, S. M., Soss, S. E., Chazin, W. J., Re-defining the 
DNA-Binding Domain of Human XPA, J. Am. Chem. Soc. 2014, 136, 10830-10833. 
42 
 
soluble human XPA98-239 construct that binds to a Y-shaped ssDNA-dsDNA 
junction and other substrates with the same affinity as the full-length protein. 
Two-dimensional 
15
N-
1
H NMR suggested XPA98-239 contains the same globular 
core as XPA98-219 and likely undergoes a conformational change upon binding 
DNA. Together, our results demonstrate that the XPA DBD should be redefined 
and that XPA98-239 is a suitable model to examine the DNA binding activity of 
human XPA. 
 
Introduction, Results and Discussion 
Nucleotide excision repair (NER) is a highly versatile DNA damage repair 
pathway that is able to remove bulky DNA lesions arising from exposure to 
sunlight, endogenous metabolites, and various environmental toxins
1,9
. Defects in 
NER result in the genetic disease Xeroderma pigmentosum (XP), a spectrum of 
disorders characterized by hypersensitivity to sunlight, dramatically increased 
incidents of skin cancer, and neurological disorders
4,12
. NER in humans involves 
the coordinated action of ~30 proteins, including seven that were identified based 
on their direct association with specific XP disorders (XPA-XPG)
3,58,150
. Among 
these, the essential XP complementation group A protein (XPA) is associated with 
the most severe clinical XP phenotypes, leading to neurodegenerative disorders, 
accelerated aging, and cancer
12
. 
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Despite its key importance to NER, XPA has no known enzymatic 
function13. However, XPA is known to bind to DNA and a number of other NER 
proteins, suggesting that it serves as a scaffold for the complex multi-protein NER 
machinery26,27,58,151. Genetic and biochemical studies suggest that DNA binding 
by XPA is crucial for the proper function of NER. Moreover, a number of XPA 
mutations associated with severe XP symptoms map to residues in the DNA-
binding domain (DBD)4,11,13. Nevertheless, there has yet to be any systematic 
biophysical and structural characterization of the interactions between XPA and 
DNA. 
The discovery of the human XPA DBD was reported nearly 20 years ago. 
Biochemical studies revealed a protease resistant domain within residues 98-219 
that was associated with binding of DNA
41
. Additional studies suggested that 
relative to ssDNA or dsDNA, XPA binds preferentially to DNA containing 
ssDNA-dsDNA junctions
37,125
. This observation was of particular interest because 
NER requires unwinding of the DNA duplex, which creates ssDNA-dsDNA 
junctions. Two solution NMR structures of XPA98-219 were subsequently 
determined
39,45
. NMR chemical shift analysis was also used to investigate binding 
of a 9 nucleotide (nt) ssDNA substrate, which enabled mapping of the interaction 
to a shallow basic cleft in XPA98-219
52
. However, the affinity for this substrate is 
extremely weak (Kd estimated to be several mM), which leads to considerable 
doubt about whether this model accurately represents how XPA interacts with  
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Figure 2.1: DNA substrates used for FA assays. Top- Y-shaped ssDNA-dsDNA 
junction containing an 8 basepair duplex with 12-nt ssDNA overhangs. Middle- 
20 basepair duplex. Bottom- 20-nt ssDNA. FL indicates the FITC fluorophore. 
 
DNA. Nevertheless, this study has remained the prevailing model to explain how 
XPA binds to the NER bubble152. We therefore set out to structurally characterize 
the interactions between XPA98-219 and a high affinity DNA substrate.  
We began by setting up crystallization trials for human XPA98-219 in 
complex with a Y-shaped ssDNA-dsDNA junction substrate that contains an 8 
basepair duplex extended by two non-complementary 12 nt ssDNA arms on one 
end of the duplex (Figure 2.1). After standard screening of conditions, crystals 
were obtained that diffracted to 2.2 Å. A concern arose during the course of 
refining the data when it was realized that based on the Matthews coefficient the 
volume of the unit cell was not sufficient to contain the mass of the protein and 
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the DNA substrate. The molecule in the crystal was assumed to be the protein 
because the volume of the asymmetric unit at 42 % solvent content could 
accommodate only one molecule of 15 kDa of XA98-219. Moreover, an absorption 
peak at 9.67 keV indicated the presence of zinc in the crystal, presumably from 
the XPA98-219 zinc motif. Before progressing with further refinement, we decided 
to determine the affinity of XA98-219 for the DNA substrate. 
 
 
Figure 2.2: XPA98-239 does not have full DNA-binding capacity of XPA. A) 
Fluorescence anisotropy assay of the binding of XPA to Y-shaped ssDNA-dsDNA 
junction (black circles, solid line), duplex (gray triangles, dashed line) and ssDNA 
(light gray diamonds, dotted line). B) Comparison of the binding of the Y-shaped 
ssDNA-dsDNA junction by full-length XPA (black circles, solid line) and XPA98-
219 (gray triangles). The concentration of the FITC tagged DNA substrate was 20 
nM and measurements were performed at room temperature in a buffer containing 
20 mM HEPES at pH 7.5, 75 mM KCl, 5 mM MgCl2, 5% glycerol, and 1 mM 
dithiothreitol. 
 
To this end, a fluorescence anisotropy assay (FA) was employed to 
directly compare the DNA-binding activity of full-length human XPA and XPA98-
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219 (Figure 2.2). Fluorescein isothiocyanate (FITC) modified ssDNA, dsDNA, and 
Y-shaped ssDNA-dsDNA junction substrates (Figure 2.1) were used for these 
analyses. Substrates of 20 nucleotides were selected for this analysis as this 
corresponds to the approximate length of DNA predicted to be occluded by one 
molecule of XPA37. The results we obtained for full-length XPA were consistent 
with previous reports; Figure 2.2-A shows that XPA binds a Y-shaped ssDNA-
dsDNA junction (0.29 ± 0.09 µM) with higher affinity than dsDNA (1.7 ± 0.6 
µM) or ssDNA (1.5 ± 0.2 µM). In stark contrast, XPA98-219 had substantially 
weaker DNA binding affinity for all three substrates, so weak that it was not 
possible to extract a Kd value even for the highest affinity Y-shaped ssDNA-
dsDNA junction (Figure 2.2-B). In order to verify that XPA98-219 was properly 
folded, a 15N-enriched sample was prepared and a 15N-1H HSQC spectrum was 
acquired. Comparison to the previously reported spectra for this construct39,45,52 
confirmed that our sample of XPA98-219 was properly folded and free of 
aggregation (Figure 2.3, red spectrum). Taken together, these results demonstrate 
that XPA98-219 lacks critical elements necessary to reproduce the full DNA-
binding activity of XPA. Thus, the widely accepted view that XPA98-219 is the 
DBD must be revised.  
The observation that XPA98-219 does not recapitulate the full activity of 
XPA led us to perform analyses of the primary sequence to search for indications 
that other residues might contribute to DNA binding. Having previously showed  
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Figure 2.3: HSQC overlay of XPA98-239 and XPA98-219. Overlay of the 800 MHz 
15
N-
1
H TROSY-HSQC spectra of XPA98-239 (black) and XPA98-219 (red) acquired 
at 35 °C in a buffer containing 20 mM Tris at pH 7.0, 150 mM KCl, and 1 mM 
DTT. The inset shows SDS-PAGE of purified XPA98-239. Lane M is the molecular 
weight marker and lane X is purified XPA98-239. 
 
that the N-terminal domain of human XPA is disordered46, we focused on the 
sequence extending towards the C-terminus. Interestingly, secondary structure 
predictions indicated that the C-terminus of XPA98-219 is located in the midst of a 
long helical element, with a high probability for helical secondary structure 
extending well beyond F219 (Figure 2.4). Moreover, there are several lysine and 
arginine residues in the region C-terminal to F219 that presumably enhance DNA 
binding affinity through electrostatic interaction with negatively charged DNA. 
Based on these insights, a series of C-terminally extended constructs were 
prepared (Figure 2.5). In all, six different human XPA constructs were cloned into 
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bacterial expression vectors. After screening for soluble expression in E. coli, the 
solubility and stability of each construct was assessed and on this basis, XPA98-239 
was selected for further analysis.  
 
Figure 2.4: Sequence analysis of XPA. Secondary structure prediction results 
from BCL::Jufo9D and Psipred with H for helical, E for extended, and C for coil 
conformation. 
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Figure 2.5: C-terminal extension XPA constructs. Top- full-length XPA, 
middle- XPA98-219, and bottom- the six new C-terminally extended DNA binding 
domain constructs. 
 
To determine if the extra C-terminal residues were important for binding 
DNA, the affinity of XPA98-239 for the 20 nt Y-shaped ssDNA-dsDNA junction, 
dsDNA and ssDNA substrates (Figure 2.1) was measured using the FA assay 
(Figures 2.6-A, 2.7). Notably, these data provided Kd values of 0.29 ± 0.08, 1.3 ± 
0.2, and 1.5 ± 0.8 µM, respectively, very similar to those for the full-length XPA, 
including the preference for  the Y-shaped ssDNA-dsDNA junction over dsDNA 
or ssDNA37,125. These results suggest XPA98-239 may be a more suitable model for 
XPA DBD than XPA98-219.
 
To verify that XPA98-239 occupies a stable conformation and is not 
aggregated, 
15
N-enriched XPA98-239 was prepared and a 2D 
15
N-
1
H HSQC 
spectrum was acquired. XPA98-239 is seen to have the characteristics of a stably 
folded 17 kDa protein, with narrow line widths and spectral dispersion evident in 
the 
1
H dimension (Figure 2.6-B, black spectrum). An overlay of the spectra of 
XPA98-219 and XPA98-239 (Figure 2.3) strongly suggests they adopt a similar 
topology and that the new construct contains the globular core. Since many of the 
peaks overlap, a significant number of the previously reported resonance 
assignments for XPA98-219 could be transferred to XPA98-239. There are 16 extra 
cross peaks in the HSQC spectrum of XPA98-239 and a limited number of them 
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could be tentatively assigned. 
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Figure 2.6: XPA98-239 exhibits the full-DNA binding of XPA.  A) Fluorescence 
anisotropy assay of the binding of the Y-shaped ssDNA-dsDNA junction (left) 
and duplex (right) substrates by full-length XPA (black circles, solid line) and 
XPA98-239 (gray triangles, dashed line). The conditions were the same as in Figure 
1. B) 900 MHz 15N-1H TROSY HSQC spectra of XPA98-239 obtained in the 
absence (black) and presence (red) of an equimolar amount of Y-shaped ssDNA-
dsDNA junction substrate. The data were acquired at 35 °C in a buffer containing 
20 mM Tris at pH 7.0, 150 mM KCl, 1 mM DTT. C) Zoomed-in view of the 
boxed region of B) showing perturbations of cross peaks from A229, W235, and 
K236 in the C-terminal extension. D) Map of NMR chemical shift perturbations 
on a surface representation of XPA98-219 (PDB ID: 1d4u). Residues identified in 
the study of XPA98-219 binding a 9-nt ssDNA substrate
18 are colored blue. 
Additional residues with significant perturbations in the study of XPA98-239 
binding the Y-shaped ssDNA-dsDNA junction substrate are c0lored salmon. See 
supplementary Methods for a detailed description of how residues with significant 
perturbations were identified. 
 
 
Figure 2.7: Binding of FL-XPA and XPA98-239 to ssDNA. Fluorescence 
anisotropy assay of ssDNA binding by XPA (black circles, solid line) and XPA98-
239 (gray triangles, dashed line). The concentration of the FITC tagged DNA 
substrate was 20 nM and measurements were performed at room temperature in a 
buffer containing 20 mM HEPES at pH 7.5, 75 mM KCl, 5 mM MgCl2, 5% 
glycerol, and 1 mM DTT. 
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These cross peaks from the C-terminal extension have the same line shape 
as the other peaks in the spectrum and are narrowly dispersed. Although 
consistent with the prediction of helical character, the available data are not 
sufficient to formally assign the structure of the C-terminal extension.  
To further characterize the interaction of XPA98-239 with DNA, we 
monitored a titration of the Y-shaped ssDNA-dsDNA junction substrate using 2D 
15N-1H HSQC NMR. This analysis showed perturbation of a select number of 
cross peaks in the spectrum that saturate at a ratio of ~1:1 (Figure 2.8), consistent 
with specific binding of this DNA substrate with low µM affinity. Comparison to 
the corresponding titration of XPA98-219 confirms that XPA98-239 binds the 
substrate much more strongly; the shorter construct is far from saturation at the 
1:1 ratio and in fact does not saturate even at a substrate ratio of 5:1 (Figure 2.8). 
These observations support the proposal that the XPA DBD had been incorrectly 
assigned. 
The NMR titration data also enabled us to test the validity of the previous 
model for the DNA binding site of XPA. In the previous study of a 9-nt ssDNA 
substrate binding to XPA98-219, chemical shift perturbations in fast exchange 
between the free and bound states were observed for 13 residues and 3 others 
were exchange broadened. Cross peaks from a larger number of residues are 
perturbed in the titration with the much higher affinity 20-nt Y-shaped ssDNA-
dsDNA junction substrate. Consistent with the higher affinity for the Y-shaped  
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Figure 2.8: DNA-binding comparison of XPA98-239 and XPA98-219 by NMR 
titration. NMR analysis of the binding of Y-shaped ssDNA-dsDNA junction 
substrate. A) 900 MHz 
15
N-
1
H TROSY-HSQC titration of XPA98-239 with Y-
shaped ssDNA-dsDNA substrate acquired at DNA: protein ratios of 0:1 (black), 
1:1 (gold), and 4:1 (red) acquired at 35 °C in a buffer containing 20 mM Tris at 
pH 7.0, 150 mM KCl, and 1 mM DTT. B) Top - Zoomed-in view of the boxed 
regions in A). Bottom corresponding regions from the 800 MHz 
15
N-
1
H TROSY-
HSQC titration of XPA98-219 acquired under the same conditions as A), but with 
the final DNA: protein ratio set to 5:1 (red). 
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substrate, both chemical shift perturbations in fast exchange and line broadening 
of resonances in intermediate exchange were observed. Figure 2.6-D maps the 
residues exhibiting significant perturbations on the previously determined NMR 
structure of the globular core; beyond the residues previously assigned to the 
DNA binding site in the study of XPA98-219 with 9 nt ssDNA (blue), the titration 
with Y-shaped substrate identified many additional perturbed residues (salmon). 
The latter include several additional residues in and around the basic cleft 
(residues L191, K204, and R207). One additional critical observation was the 
perturbation of cross peaks from three residues in the C-terminal extension (A229, 
W235, and K236, Figure 2.6-C), which strongly supports our proposal of the need 
for the C-terminal extension for full DNA binding activity. 
Our results show that XPA98-239 contains the full DNA- binding apparatus 
of human XPA, thereby redefining the XPA DBD. Mutations of residues between 
F219 and T239 are associated with severe XP disorders, which implies this region 
of the protein is critical to the function of XPA13. The incorrect assignment of 
XPA98-219 as the DBD may help explain the lack of substantial progress in 
elucidating the molecular mechanisms of XPA action in NER over the past 20 
years152. Moreover, our studies of the more physiologically relevant ssDNA-
dsDNA junction substrate clearly demonstrate the previous model for the XPA 
DNA binding site was incomplete. The new XPA98-239 DBD provides an excellent 
target for high resolution structural and biophysical investigations of the XPA-
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DNA complex that can better define its role in NER. Additionally, as increased 
cellular NER activity is often associated with loss of effectiveness of multiple 
classes of current anticancer treatments, such as radiation therapy and cisplatin153, 
XPA has been identified as a possible target for therapeutic intervention due to its 
critical role in NER154. The availability of structural information greatly enhances 
the pace of drug discovery. Hence, given the high quality NMR data presented 
here, XPA98-239 has potential as a valuable reagent for structural analyses directed 
to the design and validation of novel small molecule inhibitors and probes.  
 
Materials and Methods 
Protein Construction 
Table 2.1: PCR primers for XPA constructs. 
 
 
XPA constructs were amplified by PCR using indicated oligonucleotides (Table 
2.1) to introduce 5′ BamHI and 3′ NotI cleavage sites. Proteins were cloned into 
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the pBG100 in-house expression vector (L.S. Mizoue, Center for Structural 
Biology, Vanderbilt University), which incorporates an N-terminal human 
rhinovirus 3C (HRV3C) protease cleavable 6xHis tag.  
 
Protein Production 
All XPA constructs were overexpressed in BL21(DE3) cells. Cells were grown in 
either terrific broth or a minimal medium containing 0.5 g/L 
15
NH4Cl (CIL, Inc.) 
at 37 °C to an OD600 nm of ~0.6-0.8, then transferred to 18 °C. Protein expression 
was induced at OD600 nm ~1.0 by adding isopropyl thio-β-D-galactopyranoside to 
0.2 mM and proceeded for ~16 hours. The purification buffer was adjusted to pH 
7.0 for XPA98-239 and 8.0 for XPA and XPA98-219. All constructs were purified 
using Ni-NTA chromatography (Sigma) using standard procedures. The 6xHis 
fusion tag was removed by H3C protease cleavage followed by re-pass over Ni-
NTA resin. Size exclusion chromatography was used as the final purification step 
using either S200 (XPA) or S75 (XPA98-219 and XPA98-239) resin (GE Healthcare). 
 
Preparation of DNA Substrates 
Figure 2.1 shows the structures of DNA substrates used in this study. The position 
of the FITC tag is indicated. The DNA substrate used for the NMR study was not 
tagged. Desalted oligodeoxynucleotides were purchased from Sigma-Aldrich Co. 
(St. Louis, MO). Y-shaped ssDNA-dsDNA junctions and duplexes were prepared 
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by mixing equimolar amount of each strand in TNE buffer (10 mM Tris, 50 mM 
NaCl, 1 mM EDTA, pH 7.0), then heating in a boiling water bath and allowing 
the solution to cool to room temperature. 
 
Sequence Analysis 
The primary amino acid sequence of XPA was analyzed with a number of 
secondary structure and disorder prediction algorithms, with the final conclusions 
drawn from BCL::Jufo9D
155
 and Psipred
156
.  
 
Fluorescence Anisotropy DNA Binding Assay 
Protein and DNA substrate were diluted in binding buffer (20 mM HEPES, pH 
7.5, 75 mM KCl, 5 mM MgCl2, 5% glycerol, 1 mM dithiothreitol). Diluted 
protein was dispensed into Corning #3676 low-volume 384-well microtiter plates. 
DNA substrate was subsequently added to each well at a concentration of 20 nM. 
The plate was covered from light and incubated at room temperature for 5 
minutes prior to measuring fluorescence anisotropy to ensure samples were 
homogenized and had reached equilibrium. The fluorescence anisotropy was 
measured at room temperature using a Synergy H1 plate reader (Bio-Tek) 
equipped with a GreenFP polarization filter cube set (λEx = 485 nm, λEm = 528 
nm). Each binding measurement was performed in triplicate for each DNA 
substrate. Apparent dissociation constants (Kd) were determined for each 
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individual titration by plotting fluorescence anisotropy against protein 
concentration and fitting to a simple two-state binding model using KaleidaGraph 
(v4.03). The Kd values are reported as the mean and standard deviation of at least 
two independent measurements made on separate days from separate preparations. 
 
NMR Spectroscopy 
The NMR samples were concentrated to 50 – 100 µM in the stated buffer to 
which 5% 
2
H2O was added prior to performing the experiment. Titrations were 
performed by preparing two identical solutions of protein, one with no DNA 
substrate and the other at the highest ratio of DNA to protein, then collecting 
spectra for these and intermediate ratios created by mixing of the two solutions.   
15
N-
1
H HSQC and TROSY-HSQC spectra were recorded in 3 mm tubes at 35 °C 
using Bruker AVANCE 800 or 900 MHz NMR spectrometers equipped with a 
cryoprobe. All data were processed and analyzed using SPARKY
 
(Goddard, T.D. 
& Kneller, D. G. SPARKY 3, University of California, San Francisco.).  All 
residues whose cross peaks disappeared due to intermediate exchange line 
broadening upon binding DNA were placed in the category of significantly 
perturbed. In addition, for residues exhibiting chemical shift perturbations in fast 
exchange, we calculated the change in chemical shift (∆δ) from the spectra 
acquired with no substrate and a 1:1 ratio using the formula: ∆δ = √[(Ha - Hb)
2
 + 
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(0.2*(Na - Nb))
2
]. The threshold for significant chemical shift perturbation was set 
to the average ∆δ + one standard deviation.  
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CHAPTER III 
 
INTERACTIONS OF HUMAN XPA WITH DNA 
 
Abstract 
Xeroderma pigmentosum complementation group A (XPA) is an essential 
scaffolding protein in the multi-protein nucleotide excision repair (NER) 
machinery.  The interaction of XPA with DNA is a core function and a number of 
mutations in the DNA binding domain are associated with XP disease.  Although 
NMR structures of the core globular domain of human XPA and complementary 
data on DNA binding have been available for many years, the molecular details of 
how human XPA binds DNA remain unclear.  Insights have been obtained from 
X-ray co-crystal structures of the central globular domain of the yeast XPA 
(Rad14) in the presence of DNA, but it was unclear if these structural models 
represent DNA binding of XPA in the context of human NER.  In order to better 
understand the DNA binding activity of human XPA in NER, we used NMR to 
investigate the interaction with DNA of the human XPA DNA binding domain 
(DBD).  The data show that XPA binds different ss-ds junction DNA substrates 
similarly.  Comparisons to the crystal structures of Rad14-DNA complexes 
revealed similarities and differences between binding of DNA, including direct 
evidence of a significant role for the residues extending C-terminally from the 
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globular core.  A key site in Rad14, F262, was previously reported as critical to 
DNA binding, but mutation of the corresponding W175 in human XPA had only a 
moderate effect on DNA binding.  We also obtained insights into the molecular 
basis for XPA malfunction in disease-associated mutations in the DBD, 
suggesting a correlation may exist between the effect of mutations on DNA 
binding affinity and the severity of symptoms in XP patients. 
 
Introduction 
Nucleotide excision repair (NER) is a DNA damage repair pathway 
specialized for removing bulky lesions arising from exposure to various types of 
endogenous and exogenous toxic agents
1,2,9,157,158
.  Human NER is a multi-step 
process involving coordinated action of over 30 proteins
3,157
.  Two NER pathways 
exist, one repairs lesions in actively transcribed DNA (transcription coupled 
repair (TCR)) and the other processes lesions more generally throughout the 
genome (global genome repair (GGR)).  These differ only in the mechanism by 
which the presence of damage is recognized.  The subsequent steps, 
destabilization and unwinding of the DNA by transcription factor II H (TFIIH) to 
create a DNA structure termed the NER bubble, excision of the damaged 
nucleotide, and gap-filling synthesis, are understood to be the same
3,16,20–30,38,159–
161
.  XPA is recruited to the damage site by TFIIH once the duplex is unwound
3,38
.  
62 
 
While XPA does not have any enzymatic activity, it acts in concert with 
replication protein A (RPA) as a critical scaffolding protein through its 
interactions with DNA and other NER proteins
162
. 
Defects in NER result in the genetic disorder Xeroderma pigmentosum 
(XP), which is characterized by hypersensitivity to sunlight and increased 
incidence of skin cancer
4–7
.  In severe cases, neurological defects are also 
observed
4,11–13
.  XP arises from mutations in 8 genes, 7 of which (XPA-G) are 
directly involved in NER
18,157
.  Among these, XPA mutations are usually 
associated with most severe disease phenotypes, many of which map to the DNA 
binding domain (DBD)
11–13
.  Different XPA mutations lead to different disease 
phenotypes
4,12,13,107
; complete loss, substantial truncation, and unfolding of the 
DBD are known to lead to severe XP disease phenotypes.  However, genotype-
phenotype correlations and mechanisms behind missense mutations remain poorly 
understood
8,13,110,162,163
. 
Two structures of the globular core of the S. cerevisiae homolog of XPA, 
Rad14, have been determined for complexes with a DNA duplex containing a 
cisplatin 1,2-deoxydiguanosine intrastrand crosslink or a N-(deoxyguanosin-8-ly)-
2-acetylaminofluorene (AAF) lesion
55
.  Rad14 has remarkably higher affinity for 
these two modified duplexes than for unmodified duplexes or duplexes containing 
other lesions
55
.  The structure of the Rad14 globular core is quite similar to the 
previously reported structures of the globular core of human XPA, obtained in the 
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absence of DNA
39,40
.  However, we and others have shown that the globular core 
of human XPA (XPA98-219) does not bind DNA with appreciable affinity, and that 
a significant number of additional C-terminal residues are required for full DNA 
binding affinity
53,54
.  Consequently, the high binding affinity for the two lesion-
containing duplexes of the Rad14 globular core that lacks additional C-terminal 
residues is puzzling and suggests that the Rad14 and XPA DBDs are not 
functionally equivalent.  The uncertainty is particularly confounding in the 
context of NER because XPA is not recruited until after the presence of damaged 
DNA is recognized and unwound.   
Here we report an investigation of the interaction of human XPA with 
model NER bubble substrates using the XPA98-239 construct (XPA DBD) that 
contains the full DNA binding affinity.  We used NMR and DNA affinity 
measurements to define the binding site of XPA DBD for model NER substrates, 
and compared our findings to the structures of Rad14-DNA complexes.  To 
confirm our findings, we determined the effect of selected structure-based and 
disease-associated mutants on DNA binding.  The results revealed differences 
between the Rad14 structures and how human XPA interacts with the bubble and 
functions in NER, and insights into the molecular basis for disease association for 
certain XPA mutations. 
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Results 
Binding affinities of human XPA for ss-ds DNA junction substrates 
It had been established previously that XPA binds to a ss-dsDNA junction 
in the NER bubble
37
, although controversy remains over whether it is the 5′ or 3′ 
junction.  Moreover, the footprint of XPA on the junction remains unclear.  To 
address these issues, we measured the affinities of the XPA DBD for different 
junction structures and lengths.  We have previously used a DNA fluorescence 
anisotropy (FA) assay to characterize affinities, but turned instead here to 
microscale thermophoresis (MST) as a result of its higher precision and the 
tendency of XPA-DNA complexes to aggregate in the 384 well plates during the 
course of FA experiments.  Comparisons of the values obtained by the two 
methods revealed the same trends among substrates but higher dissociation 
constants (Kd) for MST by ~5-fold.  The systematically weaker binding in the 
MST experiments is attributable to the higher ionic strength of the buffer. 
We first confirmed that XPA DBD binds to a previously characterized 
8/12 splayed-arm substrate (Figure 3.1, Y-shaped junction with an 8 base pair 
(bp) duplex and 12 nucleotide (nt) 5′ and 3′ overhangs) with high affinity53.  
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Figure 3.1: DNA Substrates. Structures and sequences of ss-dsDNA junction 
substrates used for binding assays and NMR analyses.  The names are based on 
the number of basepairs in the duplex region followed by the number of 
nucleotides in the overhang: (1) 8/12 splayed-arm, (2) 8/12 HP splayed-arm with 
mixed sequence, (3) 8/12 HP splayed-arm, (4) 8/12 HP 3′ overhang, (5) 8/12 HP 
5′ overhang, (6) 8/10 HP 5′ overhang, (7) 8/8 HP 5′ overhang, (8) 8/6 HP 5′ 
overhang, (9) 8/4 HP 5′ overhang, (10) 8/12 5′ overhang, (11) 8/4 5′ overhang, 
(12) 8/12 3′ overhang, (13) 8/4 3′ overhang.  All hairpins (HP) are composed of 
four Ts.  The positions of fluorescein tags are indicated by [FL].  Substrate (1) 
without fluorescein tag was employed for the in-depth NMR analysis. 
 
We next sought to find a junction DNA substrate that is optimized in length and 
shape so that it interacts with XPA in a manner that avoids non-specific secondary 
binding to the substrate.  In order to systematically screen the types of junction 
and the length of overhangs, a series of DNA substrates were designed containing 
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a GC-rich duplex (sealed with a 4 nt hairpin (HP) for stability) and oligo-dT 
overhangs (Figure 3.1).  We found a modest but clearly significant difference in 
affinity for different nucleotide sequences (Figure 3.2).  
 
Figure 3.2: Structure and Sequence Dependence of XPA DBD Binding of 
Substrates.  (A) Binding of XPA DBD to 8/12 splayed-arm (circle), 8/12 HP 
splayed-arm with mixed sequence (triangle), and 8/12 HP splayed-arm (square) 
(substrates 1, 2, and 3 in Figure 3.1, respectively) as determined by fluorescence 
anisotropy binding assay.  Error bars represent standard deviation from triplicate 
experiments.  (B) Dissociation constants (Kd) determined from each curves in 
panel A. 
 
The data show that XPA DBD binds both 3′ and 5′ overhang substrates 
with approximately the same affinity as Y-shaped substrates (Figure 3.3-A, Table 
3.1).  It is interesting that the length of the overhang could be shortened to 4 nts 
without any significant effect on the affinity for substrate (Figure 3.3-B, Table 
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3.1).  The shorter overhang was advantageous for NMR studies, so we selected an 
8/4 5′ overhang substrate for detailed analysis. 
 
Figure 3.3: XPA Binding to ss-ds Junction DNA Substrates. (A) Plot of MST 
data for XPA DBD binding 8/12 splayed-arm (circle), 8/12 5′ overhang (triangle) 
and 8/12 3′ overhang (square) (substrates 3, 5 and 4 in Figure 3.1, respectively).  
(B) Plot of MST data for XPA DBD binding DNA substrates with 8 nt duplex and 
different lengths of 5′ overhangs (substrates 6–9 in Figure 3.1).  All measurements 
were made at room temperature in a buffer containing 50 mM Tris-HCl at pH 7.8, 
150 mM NaCl, 10 mM MgCl2, 0.05 % Tween-20 and 1 mM DTT.   
Table 3.1: Kd of XPA Binding to ss-ds Junction DNA Substrates.  
Dissociation constants determined from the plots in panels A and B in Figure 3.3.  
All measurements were made at room temperature in a buffer containing 50 mM 
Tris-HCl at pH 7.8, 150 mM NaCl, 10 mM MgCl2, 0.05 % Tween-20 and 1 mM 
DTT. 
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Structural analysis of the interaction of human XPA with DNA 
The binding of DNA substrates by XPA DBD (XPA98-239) was 
investigated using NMR spectroscopy.  The first step in any detailed analysis is 
the assignment of the NMR signals (resonances) to specific atoms within the 
molecule.  The NMR backbone resonance assignments for XPA DBD were 
obtained using a standard series of double and triple resonance 2D and 3D 
experiments
164
. This analysis produced assignments for 96%, 96%, 92%, 96%, 
and 94% of the 
15
N, 
1
H, 
13
CO, 
13
Cα and 13Cβ resonances, respectively (Table 3.2).  
Figure 3.4 shows the 2D 
15
N-
1
H HSQC spectrum labeled with the corresponding 
backbone peak assignments used for the titration analyses of the binding of DNA 
substrates.  Due to the extensive overlap in the spectrum, assignment of the  
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Figure 3.4: NMR Backbone Resonance Assignment of XPA DBD.  Region 
from the 600 MHz 
15
N-
1
H HSQC spectrum of XPA DBD acquired at 25 °C in a 
buffer containing 20 mM Tris at pH 7.0, 500 mM KCl, 1 mM TCEP and 5 % 
2
H2O.  To avoid cluttering of the figure, some assignment labels were removed.  
The inset is an expansion of the central region within the rectangle.   
 
 
stretch of residues between Q208 to R228 was challenging.  In this region, there 
are groups of residues that connect well; however, there are some breaks in 
between these stretches that creates more than one possibility for the assignments 
that makes sense.  In this chapter, we employed the assignment that is most self-
consistent for the analysis of NMR titration data described below. 
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Table 3.2: List of Backbone Resonance Assignment of XPA DBD. 
Residue 
# 
Assignment 
# Atom 
15
N 
(ppm) 
1
H 
(ppm) 
CO 
(ppm) 
Cα 
(ppm) 
Cβ 
(ppm) 
His-1 1 G 
     His-2 2 P 
  
177.527 63.533 32.136 
His-3 3 G 110.299 8.653 174.258 45.321 
 His-4 4 S 115.578 8.161 174.631 58.417 63.71 
98 5 M 121.95 8.419 177.6 55.632 32.707 
99 6 E 121.505 8.274 175.65 56.742 30.152 
100 7 F 119.381 7.895 174.709 
 
40.123 
101 8 D 121.248 8.207 175.022 53.952 41.206 
102 9 Y 118.01 7.683 174.985 57.509 39.808 
103 10 V 121.979 8.61 173.652 60.545 33.118 
104 11 I 123.328 7.919 175.919 58.969 37.713 
105 12 C 128.223 8.854 178.312 59.895 30.999 
106 13 E 131.505 9.509 176.128 58.346 29.959 
107 14 E 121.17 9.236 177.55 58.009 30.733 
108 15 C 117.376 8.388 177.421 59.078 32.97 
109 16 G 112.778 8.095 173.548 46.552 
 110 17 K 122.075 8.62 176.321 56.257 33.501 
111 18 E 121.368 8.525 177.049 55.97 30.383 
112 19 F 121.052 9.576 172.18 56.354 41.38 
113 20 M 118.485 8.819 175.026 56.555 34.271 
114 21 D 116.936 8.018 174.776 53.346 44.182 
115 22 S 115.75 8.248 172.442 56.162 66.315 
116 23 Y 125.94 10.55 178.576 62.626 39.476 
117 24 L 118.708 9.236 179.621 57.859 40.756 
118 25 M 123.924 8.34 178.733 57.934 32.627 
119 26 N 117.906 8.645 177.425 56.094 38.447 
120 27 H 110.576 7.698 175.319 57.938 29.591 
121 28 F 111.855 7.206 174.34 57.061 40.975 
122 29 D 116.43 7.902 174.54 55.885 39.459 
123 30 L 123.651 7.744 
 
51.589 44.619 
124 31 P 
  
173.514 62.586 28.028 
125 32 T 123.279 8.819 174.631 61.362 71.847 
126 33 C 135.292 9.797 174.917 58.544 30.548 
127 34 D 116.912 8.989 178.12 57.351 40.263 
128 35 N 120.704 8.547 176.661 56.266 38.935 
129 36 C 121.521 7.759 174.848 61.368 30.678 
130 37 R 120.61 6.863 176.714 56.853 30.106 
131 38 D 123.466 8.226 176.486 55.584 42.184 
132 39 A 126.113 8.906 177.172 53.971 19.013 
133 40 D 112.934 7.763 176.313 55.368 41.965 
134 41 D 117.235 7.144 
 
55.499 
 135 42 K 
  
178.229 60.756 32.955 
136 43 H 113.643 8.581 173.435 55.565 29.997 
137 44 K 117.42 6.739 176.176 56.434 33.598 
138 45 L 122.926 8.366 176.94 53.291 
 139 46 I 118.114 9.492 174.075 59.001 42.316 
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140 47 T 115.451 8.81 175.879 61.911 71.052 
141 48 K 121.956 8.851 177.87 60.487 33.533 
142 49 T 112.155 7.95 176.324 66.809 68.932 
143 50 E 122.934 7.957 178.529 59.721 29.702 
144 51 A 121.125 8.843 179.393 55.275 18.44 
145 52 K 114.533 8.257 176.836 60.669 32.397 
146 53 Q 116.514 7.943 177.964 58.748 29.498 
147 54 E 115.577 8.801 177.323 57.526 29.866 
148 55 Y 113.212 7.29 172.449 58.121 37.234 
149 56 L 115.574 7.036 176.154 55.633 39.186 
150 57 L 117.262 7.464 176.313 52.931 44.952 
151 58 K 121.369 9.495 178.551 54.488 35.634 
152 59 D 122.697 8.979 179.52 59.122 39.878 
153 60 C 115.154 8.621 176.364 60.197 
 154 61 D 123.277 7.406 176.144 57.186 42.887 
155 62 L 116.249 7.306 177.633 56.8 42.637 
156 63 E 113.895 8.048 179.545 57.337 32.442 
157 64 K 116.531 7.946 176.684 56.147 33.333 
158 65 R 120.047 6.948 174.543 56.511 30.355 
159 66 E 122.302 8.255 
 
54.391 32.641 
160 67 P 
     161 68 P 
  
177.481 62.985 31.932 
162 69 L 122.38 8.214 178.059 55.237 42.446 
163 70 K 125.273 9.724 173.94 56.163 34.427 
164 71 F 111.647 7.042 175.617 54.834 41.384 
165 72 I 118.005 9.232 174.925 59.514 
 166 73 V 123.288 8.522 176.014 61.439 33.151 
167 74 K 128.394 8.914 175.156 54.865 35.313 
168 75 K 124.7 8.539 176.332 56.079 32.698 
169 76 N 122.668 8.88 
 
51.253 39.472 
170 77 P 
     171 78 H 
  
177.621 58.09 32.65 
172 79 H 120.334 8.129 
 
56.441 29.188 
173 80 S 
  
175.256 59.509 63.626 
174 81 Q 121.085 8.736 176.088 56.632 28.732 
175 82 W 119.848 7.979 176.799 56.976 29.864 
176 83 G 108.651 8.254 173.663 45.556 
 177 84 D 120.646 8.259 176.076 54.625 41.515 
178 85 M 120.52 8.604 174.424 
 
35.007 
179 86 K 123.609 8.252 174.968 56.343 
 180 87 L 122.722 9.296 175.046 54.005 44.476 
181 88 Y 119.88 9.291 174.999 56.557 42.786 
182 89 L 123.095 9.386 178.243 54.746 41.5 
183 90 K 131.862 8.778 177.686 61.742 32.163 
184 91 L 117.438 9.397 179.859 58.723 41.862 
185 92 Q 116.779 7.191 178.552 58.394 27.874 
186 93 I 123.882 7.689 177.298 60.927 34.341 
187 94 V 120.707 8.6 179.147 66.815 31.617 
188 95 K 118.67 7.212 178.723 60.06 32.368 
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189 96 R 119.42 8.038 177.954 56.669 27.915 
190 97 S 116.016 8.956 176.179 62.631 
 191 98 L 121.937 7.855 180.738 57.775 41.212 
192 99 E 121.163 7.926 178.823 58.977 29.665 
193 100 V 118.519 7.954 178.033 65.827 32.44 
194 101 W 117.443 8.639 177.696 58.809 30.115 
195 102 G 111.573 8.129 174.109 46.689 
 196 103 S 109.931 7.54 173.65 57.132 65.676 
197 104 Q 122.665 9.262 177.975 58.459 28.133 
198 105 E 118.993 9.001 178.869 60.71 28.635 
199 106 A 122.793 8.109 180.71 54.969 19.065 
200 107 L 121.845 7.349 177.668 58.095 41.045 
201 108 E 117.687 8.313 179.887 59.422 28.356 
202 109 E 120.033 8.098 178.352 59.264 29.307 
203 110 A 122.349 7.552 180.727 54.749 18.645 
204 111 K 118.703 8.044 178.883 59.722 32.427 
205 112 E 120.268 7.769 178.711 58.865 28.95 
206 113 V 119.241 7.91 177.882 64.754 31.933 
207 114 R 120.449 7.843 
 
58.057 30.11 
208 115 Q 
  
175.267 56.34 30.481 
209 116 E 118.305 7.762 175.387 55.883 29.779 
210 117 N 117.843 8.403 176.714 
 
32.917 
211 118 R 121.939 8.188 175.92 56.846 32.69 
212 119 E 121.219 8.197 178.032 58.173 30.387 
213 120 K 120.202 8.28 178.041 57.956 29.602 
214 121 M 120.264 8.097 177.952 57.768 32.432 
215 122 K 119.024 8.039 177.178 56.502 32.36 
216 123 Q 120.999 8.008 177.234 57.342 32.615 
217 124 K 120.081 8.134 177.296 57.561 28.53 
218 125 K 120.773 8.377 177.809 58.271 29.676 
219 126 F 118.425 8.335 176.633 54.652 38.433 
220 127 D 121.018 8.184 175.555 58.028 39.477 
221 128 K 122.049 8.281 176.351 56.94 32.85 
222 129 K 121.547 8.134 176.91 56.924 32.802 
223 130 V 121.73 8.275 177.178 56.949 32.448 
224 131 K 120.94 8.032 176.585 63.208 32.747 
225 132 E 124.097 8.245 
 
56.898 32.747 
226 133 L 
     227 134 R 
  
177.008 63.832 32.148 
228 135 R 117.486 8.184 176.122 56.224 30.81 
229 136 A 125.164 8.271 177.776 52.531 19.239 
230 137 V 119.463 8.074 176.391 62.497 32.64 
231 138 R 124.598 8.38 176.335 56.213 30.792 
232 139 S 117.062 8.33 174.703 58.383 63.908 
233 140 S 117.894 8.373 174.617 58.544 63.686 
234 141 V 120.635 7.989 175.852 62.494 32.44 
235 142 W 124.227 8.064 175.744 57.324 29.597 
236 143 K 123.776 7.885 175.47 55.852 33.426 
237 144 R 122.722 8.12 176.145 56.135 30.633 
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238 145 E 123.009 8.483 175.845 56.697 30.44 
239 146 T 120.154 7.813 
 
63.196 70.675 
 
The results from NMR titrations of 
15
N-enriched XPA DBD with different 
DNA substrates were used to map the interaction surface of XPA DBD (Figure 
3.5).  Overall, the trends in chemical shift perturbations (CSPs) were the same for 
the different substrates.  Major perturbations were found in the globular core 
between residues 130 – 210, and in residues extending C-terminally from the core 
between residues 215 – 230 (Figure 3.5).  The N-terminal region of the globular 
core containing a zinc finger was unaffected except for a single residue D152, 
whose side chain is presumably engaged in a salt bridge that spans to the DNA 
binding site. 
 
Figure 3.5: Chemical Shift Perturbations (CSPs) Induced by DNA Substrates.  
CSPs for each residues observed from the NMR titration of XPA DBD with 8/12 
splayed-arm, 8/12 5′ overhang, 8/12 3′ overhang, and 8/4 3′ overhang DNA 
(substrates 1 without fluorescein tag, 10, 12, and 13 in Figure 3.1, respectively).  
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Peaks exchange broadened upon DNA binding are shown as open bars.  Only the 
chemical shifts that were perturbed above the threshold are shown. 
 
While the overall patterns are similar, each substrate had some unique 
features.  For example, only the junctions with 5′ overhangs induced CSPs of the 
resonances of L138, E156, and V223.  These observations reflect the XPA DBD 
adapting to the substrate.  Notably, XPA has appreciably lower affinity for blunt 
end duplex substrates
37
 and the CSPs were small relative to junction substrates.  
However, no direct correlation was observed between the magnitude of the CSPs 
and the binding affinities among the junction substrates. 
An in-depth analysis was performed for the titration of 
15
N labeled XPA 
DBD with the 8/4 5′ overhang substrate (Figure 3.1).  Significant CSPs were 
observed primarily in the C-terminal portion of XPA DBD including β3, α1, the 
hairpin between β4 and β5, the C-terminal end of α3, and a number of residues in 
the C-terminal extension (Figure 3.6).  Of the 33 residues perturbed by addition of 
the substrate, 17 exhibited fast exchange on the NMR time scale, whereas the 16 
others exhibited intermediate exchange and were broadened beyond detection.  
Making the logical assumption that all CSP arise from the same DNA binding 
phenomenon, the residues with broadened signals have the largest chemical shift 
differences between the free and bound state and are presumed to be centered in 
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the binding site.  This group of residues is highlighted in Figure 3.6-B, which 
shows the CSPs mapped on the NMR structure of the XPA globular core.   
 
 
Figure 3.6: NMR Titration of XPA DBD with 8/4 5′ Overhang DNA.  A) 
Overlay of the 900 MHz 
15
N-
1
H HSQC spectrum of XPA DBD in the presence 
(red) and absence (black) of 8/4 5′ overhang DNA (Figure 3.1, 11).  Spectra were 
acquired in a buffer containing 20 mM Tris, pH 7.0, 150 mM KCl, 1 mM Tris(2-
carboxymethil) phosphine (TCEP), and 5 % 
2
H2O.  B) CSPs from spectra shown 
in A mapped on the 1XPA structure.  Significant CSPs of C-terminal residues are 
mapped on the amino acid sequence below the structure.  C) Plot of CSPs versus 
residue number from the spectra shown in A.  Peaks exhibiting exchange 
broadening are shown as open bars.  The threshold for significant CSP is 
indicated by the dashed line.   
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Comparison of DNA binding by human XPA DBD versus the yeast Rad14 
globular core 
The CSPs were also used to map the residues involved in binding DNA by 
XPA onto the structures of the Rad14 X-ray crystal structures and onto a 
homology model of the XPA DBD.  Figure 3.7 shows ribbon diagrams of the 
yeast crystal structures and the XPA homology model based on one of the Rad14 
crystal structures (PDB ID: 5A3D), with residues highlighted that are involved in 
DNA binding identified by the NMR.  
Most of the residues involved in contacts with DNA in the Rad14 crystal 
structures exhibit CSPs in the NMR titrations of the human XPA DBD.  However, 
the NMR study revealed many additional residues with significant CSPs induced 
by the binding of DNA.  The most important difference were the CSPs observed 
in the extra 20 C-terminal residues extending beyond the globular core, which are 
not present in the Rad14 construct (Figure 3.7).  These CSPs are fully consistent 
with our previous analysis showing that the C-terminal extension beyond the 
globular core is essential to recapitulating the DNA binding affinity of full-length 
XPA
53
.  Two residues, T239 and H258, contact the DNA in the structure of 
Rad14, but the corresponding residues in XPA DBD (K151 and H171) did not 
exhibit a CSP in the DNA titrations.  The absence of an effect on K151 is likely 
due to a structural adjustment in the flexible loop in which it is found; both  
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Figure 3.7: Comparing DNA-binding Residues Identified in Rad14 Crystal 
Structures and NMR Analyses of Human XPA.  Mapping of DNA-binding 
residues identified in the Rad14 crystal structures (A) and NMR titrations (B) on 
the homology model of human XPA102-214.  (C) Sequence alignment of human 
XPA (top) and S. cerevisiae Rad14 (bottom).  DNA binding residues are colored 
red. The residues reported to be mutated in cancer patients are indicated by 
underlines (missense mutations only). 
 
neighboring residues around K151, L150 and D152, showed significant CSPs 
(Figure 3.7) suggesting one of these residues replaces the T238 contact.  As for 
H171, the NMR analysis indicates K168, K179, K221, K222, and K224 are 
involved in DNA binding, but the Rad14 crystal structure suggests that among 
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these only K179 contacts the DNA.  We note that our findings are consistent with 
the results of a previous mass spectrometry foot printing study that reported 6 
XPA lysine residues (K168, K179, K221, K222, K224, K236) are involved in the 
binding of junction DNA
54
.   
The F262A mutation in Rad14 was reported to cause complete loss of 
binding to damage-containing duplexes, suggesting the critical importance of this 
residue in DNA binding by yeast Rad14
55
.  The equivalent residue in XPA, W175, 
showed a significant CSP (Figure 3.6), consistent with its involvement in binding 
DNA and the positioning of the side chain in the homology model.  However, 
when the DNA binding of a W175A mutant was tested, only a slight reduction in 
DNA binding affinity to the NER model substrates was observed (Figure 3.8-A, 
Table 3.3).   
 
Mutation of residues in the C-terminal extension of XPA DBD inhibit binding 
of DNA 
In order to investigate the contribution of residues 220–239 to DNA 
binding more closely, we prepared a series of mutations of basic residues in this 
region.  Three charge reversal, single-site mutations (K221E, K222E, R228E) 
resulted in mild reduction in DNA binding affinity, whereas the double mutation 
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K221E/R228E had a much more dramatic effect (Figure 3.8-B, Table 3.3).  
Truncations of the DBD also caused significant reductions in DNA binding  
 
Figure 3.8: DNA Binding of Mutant XPA.  MST analyses of DNA binding 
constants of WT XPA DBD and (A) W175A mutant, (B) mutations of residues in 
the C-terminal extension from the globular core, (C) truncation mutants, and (D) 
disease-associated missense mutants.  All experiments used the 8/4 HP 5′ 
overhang DNA (Figure 3.1, 9).  
 
Table 3.3: DNA Binding of Mutant XPA.  Table of dissociation constants (Kd) 
extracted from the MST data plotted in panels A–D in Figure 3.8.  All 
measurements were made at room temperature in a buffer containing 50 mM Tris-
HCl at pH 7.8, 150 mM NaCl, 10 mM MgCl2, 0.05 % Tween-20 and 1 mM DTT.  
Asterisk shows that the binding was too weak to accurately determine Kd values.  
 
80 
 
 
 
affinity (Figure 3.8-C, Table 3.3).  Although both truncation mutants retained 
some DNA binding activity, the shorter construct XPA98-227 had weaker DNA 
binding activity than the longer XPA98-234.  These results confirm that the cluster 
of basic residues in the C-terminal of XPA DBD contribute significantly to DNA 
binding.   
 
Insights into the molecular basis of XPA disease-associated mutations 
Our biophysical and structural studies of DNA binding by the XPA DBD 
provide information to enhance the general understanding of genotype-phenotype 
correlations for XPA mutations.  The available data is limited, especially for 
many missense mutations discovered in cancer patients
162
, simply because there 
have been few investigations of phenotypes or biochemical malfunctions of 
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specific XPA mutants.  The results reported here enable some genotype-
phenotype correlations to be made.  For example, XP-A patients expressing 
truncation mutant XPA1-227 are known to exhibit mild neurological disorders 
while those with XPA1-220 have severe neurological symptoms
13
.  Our current and 
previous data show that XPA DBD truncated at R227 retains weak DNA binding 
(Figure 3.8-C, Table 3.3), whereas truncation at F219 barely retains any DNA 
binding activity
53
.  These observations suggest a correlation exists between the 
degree of inhibition of XPA DNA binding activity and XP disease phenotype.  
The observation of charge reversal mutations of K221 and R228 causing only 
very small reductions in DNA binding (Figure 3.8-B, Table 3.3) therefore 
suggests that the K221Q and R228Q mutations will result in mild disease 
symptoms. 
Insights were obtained for three additional disease-associated mutants, 
V166A, L191V and R207Q.  These mutations were prepared in the XPA DBD 
construct, expressed and purified, then their structural integrity and DNA binding 
affinity were characterized.  In WT XPA DBD, V166 did not have a significant 
CSP upon binding of DNA but is between residues that did (I165 and K167), 
L191 is distant from residues affected by DNA binding, and R207 has a 
significant CSP (Figure 3.7).  As anticipated, L191V did not cause any significant 
effect on DNA binding, whereas R207Q caused a dramatic decrease in DNA 
binding affinity.  The data for V166A were more surprising. 
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Interestingly, we were unable to concentrate V166A sufficiently to 
conduct the DNA binding assay, suggesting reduced stability of this mutant.  We 
were however able to establish that the structural integrity of this mutant was 
maintained, as both the NMR and CD spectra were similar to the WT protein 
(Figure 3.9).  To determine if the mutation altered the stability of the domain, 
thermal denaturation experiments were performed by CD for the mutant and the 
WT protein (Figure 3.9-B), revealing that the V166A mutation has a 4 °C lower 
apparent thermal denaturation mid-point (Tm) than the WT.  Hence, although the 
V166A mutation does not grossly alter folding, it does significantly reduce the 
stability of the globular core.  Interestingly, in the Rad14 crystal structures and 
homology models of XPA, the V166 residue is a part of the β-hairpin that 
intercalates into the ss-dsDNA junction.  A likely explanation for the decreased 
stability could be the loss of hydrophobic interactions that support the cross-
strand interaction in the β-hairpin.  Given its important role in XPA binding of 
DNA, destabilization of the β-hairpin may well prove to be the biochemical 
malfunction at the origin of disease-association.  
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Figure 3.9: V166A Mutant is Less Stable than WT XPA (A) Overlay of 
1
H 1D 
NMR spectra of XPA DBD WT (blue) and V166A (red).  (B) CD thermal 
denaturation curves of WT (black) and V166A (gray) XPA DBD.  Melting 
temperatures (Tm) were measured from the maxima of the derivatives of each 
curve, resulting in values of 45.5 °C for WT and 41.5 °C for V166A.  
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Discussion 
XPA is central scaffold for human NER machinery, and although loss of 
DNA binding activity of XPA is anticipated to lead to severe XP symptoms
8
, 
XPA binding to the NER bubble and its effect on NER efficiency or correlation to 
XP symptoms have not been investigated.  One contributing factor was that the 
DNA binding domain had been incorrectly assigned to the XPA globular core, 
which has only weak affinity for DNA
41,53
.  Important new insights were obtained 
recently when the first high-resolution structures in the presence of DNA were 
reported for the yeast homolog of XPA, Rad14
55
.  However, whether or not these 
structures serve as accurate models for human XPA in the context of NER 
remains unclear because the DNA substrates in the crystal structures were 15 or 
16-bp DNA duplexes modified at the center with specific lesions.  These 
substrates are not representative of canonical NER as XPA is not recruited to the 
site of damage until TFIIH unwinds the damaged DNA
3,38
.  The specific lesion-
containing duplexes appear to be very unique substrates because in general, XPA 
binds ss-ds junctions much more tightly than duplexes.  Indeed, Rad14 binds 
unmodified duplexes and other lesion-containing duplexes with substantially 
lower affinity than duplexes modified with cisplatin and AAF
55
.  XPA has been 
shown to interact with proteins not involved in NER (e.g. XPA binding 
proteins
103–106
 and PCNA
92,162
) and it is conceivable that the Rad14 structures 
reveal the molecular basis of DNA interactions in the other pathways for cellular 
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processing or bypass of damaged DNA.  Regardless, structural information on 
human XPA in complex with NER substrates is required to better understand the 
molecular basis of XPA function in NER.     
We have investigated the interaction of human XPA with DNA using a 
DBD construct that exhibits the same DNA binding affinity as the full-length 
protein and ss-dsDNA junction substrates that model the NER bubble created 
after the damaged duplex is unwound by TFIIH.  NMR backbone resonance 
assignments allowed identification of the residues affected by binding to DNA 
substrates.  Analysis of different DNA substrates resulted in similar CSPs, 
suggesting that the same set of residues is involved in DNA binding for variety 
DNA structures with different binding affinities.  For the most part, there was a 
good correlation between NMR CSPs of residues in the globular core and the 
corresponding DNA binding site in the yeast Rad14 crystal structures.  The NMR 
analysis revealed significant DNA contacts with residues in the C-terminal 
residues that extend beyond the globular core and are missing from the yeast 
construct.  As a result, uncertainties remain as to whether the Rad14 structures 
provide a sufficient model for DNA binding by XPA. 
The relevance of the Rad14 model is further limited by the fact that two 
Rad14 molecules are engaged, one on either end of the lesion-containing duplex.  
Interaction in this manner is inconsistent with current NER models, which include 
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only a single XPA molecule in the pre-incision and incision complexes.  That said, 
it is conceivable that the end-on mode of interaction of Rad14 is in some way 
mimicked when XPA is engaged at the ss-dsDNA junction within the NER 
bubble.  However, the yeast and human proteins do not completely correspond; 
for example, the W175A mutant of XPA DBD binds DNA with similar affinity as 
WT, whereas the corresponding F262A mutant in the Rad14 globular core 
completely abolished binding to DNA.  These results provide further evidence of 
the need for high-resolution structures of complexes of XPA with NER substrates. 
Residues C-terminal to the globular core contribute significantly to the 
binding of NER model substrates. Our mutational analysis of basic residues at the 
C-terminus of XPA DBD shows that multiple residues collectively contribute to 
the high affinity to DNA.  These studies also shed light on genotype-phenotype 
relationships for certain XPA mutants; in particular, we believe a correlation 
exists between the effect of mutation on DNA binding affinity and severity of 
symptoms in XP patients.  However, DNA binding affinity is but one of several 
factors that can contribute to biochemical malfunction of disease-associated 
mutations.  For example, we found that the V166A mutation is destabilized 
compared to the WT protein, which could affect not only DNA binding, but also 
protein interactions and cellular turnover.  R207 presents another interesting 
example.  We found that the disease-associated R207Q mutation has significantly 
weakened DNA binding affinity, whereas a host reactivation assay showed that 
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the R207E mutant is capable of the repair of UV lesions
65
.  The assay is not 
sensitive to effects on the rate of repair, which may be compromised when DNA 
binding affinity is diminished.  Moreover, this residue is also important for 
interactions with the NER factor XPE
48
.  The remarkably rapid progress in recent 
years in structural analysis of large multi-protein complexes, such as those 
assembled along the trajectory of NER, holds promise for dissecting such 
complex relationships.  Systematic functional analyses, for example of UV lesion 
repair efficiency, will also be required to attain the ultimate objectives of a more 
complete understanding of the relationship of XPA DNA binding affinity to NER 
activity and the genotype-phenotype correlation of disease-associated mutations. 
 
Materials and Methods 
XPA DBD Mutant Construction 
We previously reported the construction and purification of XPA DBD 
(XPA98-239)
53
.  Using this pBG100 XPA DBD plasmid as the template, site single 
mutations were introduced using the Q5 site-directed mutagenesis kit (New 
England BioLabs, Inc.) following the manufacturer’s protocols.  The 
K221E/R228E double mutant was created using K221E primers and pBG100 
XPA DBD R228E plasmid as the template.  Primers for mutagenesis are listed in 
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Table 3.4.  For the truncation mutants R228X (XPA98-227) and W235X (XPA98-234), 
XPA constructs were amplified by PCR using the oligonucleotides indicated in 
Table 3.4 to introduce 5′ BamHI and 3′ NotI cleavage sites.  All mutants were 
cloned into the pBG100 in-house expression vector (L. S. Mizoue, Center for 
Structural Biology, Vanderbilt University), which incorporates an N-terminal 
human rhinovirus 3C (HRV3C) protease cleavable 6xHis tag.  
 
Table 3.4: Primer Sequences for XPA DBD Mutant Construction 
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DNA Substrate Preparation 
Figure 3.1 shows the structures of DNA substrates used in this study.  The 
position of the FITC tag is indicated if applicable.  Desalted 
oligodeoxynucleotides were purchased from Sigma-Aldrich Co. (St. Louis, MO).  
Y-shaped ssDNA-dsDNA junctions, and duplexes were prepared by mixing an 
equimolar amount at 0.5 – 1 mM of each strand in the buffers listed below for 
NMR or DNA binding experiments.  Then the mixture was heated in a boiling 
water bath and allowed to cool to room temperature for annealing.  Hairpin-
containing DNA substrates were dissolved in TNE buffer (10 mM Tris, 50 mM 
NaCl, 1 mM EDTA, pH 7.0) at 2 µM concentration and annealed by heating in a 
boiling water bath followed by immediate cooling on ice.  
 
XPA DBD Production 
WT and mutant XPA DBD proteins were expressed and purified as 
described previously
53
.  The XPA DBD used for NMR titrations was expressed in 
minimal media containing 0.5 g/ L of 
15
NH4Cl (CIL, Inc.).  The preparations of 
samples for backbone resonance assignments also contained 2 g/ L 
13
C6-glucose 
(CIL, Inc.).  
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Analysis of DNA Binding by Fluorescence Anisotropy 
The basic protocol for the fluorescence anisotropy DNA binding assay 
was described previously
53
. 
 
Analysis of DNA Binding by Microscale Thermophoresis
128,129,165,166
 
Proteins were dialyzed into the MST buffer (50 mM Tris-HCl at pH 7.8, 
150 mM NaCl, 10 mM MgCl2, 0.05 % Tween-20 and 1 mM DTT).  Fluorescein-
labeled DNA stocks were also diluted in MST buffer.  All samples and buffer 
were passed through a 0.2 µm filter.  For each experiment, sixteen dilutions of the 
protein were prepared to varying concentrations.  DNA was added to each of the 
sample to the final concentration of 40 nM in the tubes provided in the Monolith 
NT.115 Series Standard Treated Capillaries kit (NanoTemper, Inc.).  All 
experiments were carried out at room temperature using the capillaries in a 
Monolith NT.115 Blue/Red instrument (NanoTemper, Inc.) at 20 % LED power 
and 40 % MST power.  Data were analyzed using MO.Affinity software 
(NanoTemper, Inc.). 
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Circular Dichroism 
Samples of XPA DBD WT and V166A mutant were dialyzed into a buffer 
containing 20 mM Tris at pH 7.0, 150 mM KCl, and 1 mM DTT.  All samples 
and buffer were passed through a 0.2 µm filter before data collection.  The 
concentration of protein was adjusted to 11 µM prior and far-UV CD data were 
collected at 220 nm over the range 15–65 °C using a Jasco J-810 CD 
spectropolarimeter (Easton, MD). 
 
Generation of the XPA DBD Homology Model 
A homology model of human XPA102-214 was generated using the X-ray crystal 
structure of S. cerevisiae Rad14 (PDB ID: 5A3D) as template for calculations 
using Modeller 9.14
167
.    
 
1
H 1D NMR Analysis of XPA DBD V166A 
XPA DBD WT and V166A mutant were concentrated to 30 µM in a 
buffer containing 20 mM Tris, pH 7.0, 75 mM KCl, 1 mM TCEP to which 5% 
2
H2O was added prior to performing the experiment.  
1
H 1D spectrum of each 
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sample was acquired in a 3 mm tube at 25 °C using a Bruker AVANCE 600 MHz 
spectrometer equipped with a cryoprobe. 
   
NMR Backbone Resonance Assignments 
13
C,
15
N-enriched XPA DBD was concentrated to 460 µM in a buffer 
containing 20 mM Tris, pH 7.0, 500 mM KCl, 1 mM TCEP and 5 % 
2
H2O.  
15
N-
1
H HSQC and a series of heteronuclear triple resonance 3D experiments (HNCO, 
HNCA, HNCACB, and CBCACONH)
120
 were acquired in a shaped tube at 25 °C 
using a Bruker AVANCE 600 MHz spectrometer equipped with a cryoprobe.  All 
3D data were collected using non-uniform sampling (NUS)
168–173
 and were 
reconstructed using Topspin (Bruker).  Further data processing and figure 
preparations were carried out using SPARKY (Goddard, T.D. & Kneller, D. G. 
SPARKY 3, University of California, San Francisco).  Resonance assignments 
were obtained using NMRview software (One Moon Scientific).   
 
NMR Titration of XPA DBD with DNA 
All samples for DNA titrations were concentrated to 50 µM in the NMR 
buffer containing 20 mM Tris, pH 7.0, 150 mM KCl, 1 mM Tris(2-
carboxymethil) phosphine (TCEP), and 5 % 
2
H2O.  Titrations were performed at 
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25 °C using a Bruker AVANCE 800 or 900 MHz spectrometer equipped with a 
cryoprobe following the procedure described previously
53
.  A second titration 
with 8/4 5′ overhang substrate was performed in the NMR buffer with 250 mM 
instead of 150 mM KCl to enable transfer of the assignments from the conditions 
used for obtaining resonance assignments. 
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CHAPTER IV 
 
DISCUSSION AND FUTURE DIRECTIONS
3
 
 
Summary of This Work 
 Among numerous factors involved in human NER, XPA seems to play a 
critical role as indicated by the fact that XPA mutations are associated with severe 
XP disorder symptoms.  This is especially true for those mutations found within 
XPA DBD, containing interaction motifs for DNA and RPA70AB.  This 
dissertation research set out to elucidate molecular basis of XPA-DNA and XPA-
RPA interactions at XPA DBD.  Key findings from this project are summarized 
below. 
 
Revised DNA binding domain of XPA 
 For the past ~20 years, XPA98-219 had been termed the XPA DNA binding 
domain
41
.  Numerous biochemical and structural studies have been performed 
based on this study.  However, my DNA binding assays showed that the DNA 
binding of XPA98-219 is significantly weaker than that of FL-XPA
53
.  Based on 
sequence analysis of XPA suggesting that the C-terminus of XPA98-219 is in the 
                                                          
3
 Part of this chapter was published in Sugitani, N., Sivley, R. M., Perry, K. P., Capra, J. A., 
Chazin, W. J., XPA: A Key Scaffold for Human Nucleotide Excision Repair, DNA Repair, 2016, 
44, 123-135.  Contents reused under permission by Elsevier (license #: 4063671121717). 
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middle of a long C-terminal helix, new XPA constructs extending towards the C-
terminus were constructed.  Subsequent DNA binding assays and NMR analysis 
confirmed that XPA98-239 construct is a well folded construct that contains full 
DNA binding activity comparable to FL-XPA
53
.  Consistent with this discovery, 
another group also reported that there are critical lysine residues beyond residue 
F219 that are involved in DNA binding
54
.   
 
Comparison of DNA binding by human XPA and S. cerevisiae Rad14 
Although NMR structures of the core globular domain of human XPA
39,174
 
and complementary data on DNA binding
26,37
 have been available for many years, 
the molecular details of how human XPA binds DNA remain unclear.  Insights 
have been obtained from X-ray co-crystal structures of the central globular 
domain of the yeast XPA (Rad14) in the presence of DNA
55
, but the construct 
lacked the corresponding C-terminal residues that were shown to be critical to the 
DNA binding activity of XPA (Figures 1.6, 3.7).  Moreover, the duplex DNA 
substrates do not correspond to DNA structures encountered by XPA as it 
functions in NER machinery
3,37,38
.  NMR studies of human XPA DBD using ss-
dsDNA junction substrates revealed which residues are affected upon DNA 
binding, including those from C-terminal extension.  Mutations of these C-
terminal residues confirmed that the cluster of basic residues in this region is 
important for DNA binding (Figure 3.8-B and C).  Moreover, a key site in Rad14, 
97 
 
F262, was previously reported as critical to DNA binding
55
, but mutation of the 
corresponding W175 in human XPA had only a moderate effect on DNA binding 
(Figure 3.8-A). 
  
DNA binding activity of disease-associated XPA mutants 
 Effects of select disease-associated XPA mutants on DNA binding were 
investigated.  Consistent with the NMR titration of XPA DBD with ss-dsDNA 
junction substrates (Figure 3.7-C), missense mutant R207Q showed significant 
reduction in DNA binding while L191V did not (Figure 3.8-D).  Comparing the 
DNA binding of truncation mutants XPA98-219, XPA98-234, and XPA98-227 to XPA 
DBD confirmed that the shorter the C-terminal extension is, the weaker is the 
DNA binding activity of XPA (Figures 2.2, 2.6-A, and 3.8-C).  Patients 
expressing truncation mutant XPA1-227 are known to exhibit mild 
neurodegeneration
13
.  Interestingly, it was also observed that while it doesn’t 
result in complete unfolding of the protein, the V166A mutant is less stable 
compared to WT XPA (Figure 3.9).  This reduction in stability could influence 
XPA activity within NER pathway. 
 
Defining the site of interaction of the XPA globular core with RPA70AB 
 There are two interaction sites between XPA and RPA.  The major 
interaction occurs between N-terminus of XPA and RPA32C domain
46
 while a 
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weaker, secondary interaction occurs between the globular core of XPA and the 
RPA70AB domain (Figure 1.3) 
45,87,88
.  The molecular basis of the interaction 
between the XPA globular core and RPA70AB was unclear because there were 
two conflicting proposals in the field.  Whereas one model suggested that the N-
terminus of the XPA globular core containing the zinc finger is responsible for 
RPA70AB interaction
39,45
, a second suggested that the C-terminal region of the 
globular core is involved and that RPA70AB binding site overlaps with DNA 
binding residues
89,90
.  My NMR titration of XPA globular core with RPA70AB 
showed that the N-terminal region of XPA DBD is responsible for the interaction 
with RPA70AB and this binding site is independent of the DNA binding residues 
within XPA DBD.  A reverse NMR titration indicated that the binding sites for 
ssDNA and XPA globular core are spatially proximate on RPA70AB.  When the 
XPA globular core was added to RPA70AB-ssDNA complex, it did not displace 
the DNA but induced CSPs to the residues near the ssDNA binding site of 
RPA70AB.  These results indicate that the XPA globular core, ssDNA and 
RPA70AB can form a ternary complex.   
 
Implication of the Results 
 As summarized above, this study has expanded understanding of XPA 
interactions with DNA and RPA as well as mutations at the XPA DBD.  This 
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section discusses implication of these results in understanding human NER and 
XP disorders.   
 
Differences in DNA binding of human XPA versus the structural model of S. 
cerevisiae Rad14-DNA complex 
Recently determined crystal structures of yeast homolog of XPA, Rad14, 
in the presence of DNA provided important new insights in XPA-DNA 
interaction
55
.  However, whether or not these structures serve as accurate models 
for human XPA in the context of NER remains unclear.  The DNA substrates 
used for the study were duplex DNA with lesions at the center.  Moreover, high 
affinity binding of the Rad14 DNA binding construct was observed only for 
duplex DNA containing either the cisplatin or AAF adduct lesions; much lower 
affinity was observed for unmodified duplexes or those containing different 
lesions
55
.  Importantly, these substrates are not representative of canonical NER 
as XPA is not recruited to the site of damage until TFIIH unwinds the damaged 
DNA
3,38
.  
XPA binds ss-ds junctions much more tightly than duplexes
37
.  XPA has 
been shown to interact with proteins not involved in NER (e.g. XPA binding 
proteins
103–106
 and PCNA
92,162
) and it is conceivable that the Rad14 structures 
reveal the molecular basis of DNA interactions in unforeseen ways or in other 
pathways for cellular processing or bypass of damaged DNA.  It is also possible 
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that these crystal structures suggest specialized sub-pathways of NER that are not 
yet discovered.  Regardless, structural information on human XPA in complex 
with proper NER substrates is required to better understand the molecular basis of 
XPA function in canonical NER. 
In this dissertation work, we employed the re-defined XPA DBD construct 
that exhibits the same DNA binding affinity as the full-length protein and ss-
dsDNA junction substrates that model the NER bubble created after the damaged 
duplex is unwound by TFIIH.  NMR backbone resonance assignments as well as 
NMR titrations revealed that the same set of residues is involved in DNA binding 
for variety DNA structures with different binding affinities.  There was some 
agreement between the DNA binding residues determined from our NMR studies 
and from the Rad14 crystal structures in the globular core.  However, NMR 
analysis showed significant DNA contacts with residues in the C-terminal 
residues that extend beyond the globular core and are absent from the yeast 
construct.  Our mutational analysis supports that the proposal that multiple basic 
residues in the C-terminal extension collectively contribute to the high affinity to 
DNA.  Therefore, uncertainties remain as to whether the Rad14 structures provide 
a sufficient model for DNA binding by XPA.  It is conceivable that C-terminal 
extension of Rad14 to better correspond to human XPA DBD would result in 
DNA binding properties similar to human XPA DBD.   
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It is possible that the end-on mode of interaction of Rad14 may in some 
way be mimicked when XPA is engaged at the ss-dsDNA junction within the 
NER bubble.  However, it is difficult to imagine that two molecules are engaged 
in the manner of Rad14, with one at each end of the lesion containing duplex as 
shown in the crystal structures.  This type of intermediate DNA structure with 
XPA would not be present at any point of NER.  It was also striking to find that 
W175A mutant of XPA DBD binds DNA with similar affinity as WT, whereas 
the corresponding F262A mutant in the Rad14 globular core completely abolished 
binding to DNA.  These results further support the importance of high-resolution 
structures of complexes of XPA with appropriate NER substrates to fully 
characterize XPA-DNA interactions in terms of human NER. 
 
XPA is not likely dimerized at the NER bubble 
 Binding of XPA to a ss-dsDNA junction of the NER bubble is well 
established
37,55
.  As discussed in Chapter I, whether XPA binds to the junction 5′ 
or 3′ to the lesion remains unclear.  Interestingly, characterization of XPA in vitro 
has revealed that XPA can form a dimer
92
.  It may be possible for two molecules 
of XPA to interact with each ss-dsDNA junction of the NER bubble, particularly 
in vitro with an isolated NER bubble and purified XPA.  However, considering 
the extensive network of protein-protein interactions of XPA, it is difficult to 
imagine two molecules of XPA could interact simultaneously with the NER 
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bubble.  For example, as described in Appendix A, the XPA globular core 
interacts with DNA and RPA70AB at one of the ss-dsDNA junction of the NER 
bubble.  Moreover, the undamaged ssDNA strand of the NER bubble is just long 
enough to accommodate one molecule of RPA.  So, if a second XPA molecule 
was bound to the bubble, it will have to compete with the first molecule for the 
binding site of RPA as well as other NER proteins. 
 
Correlation between XPA mutations and XP disease symptoms 
This work has provided insights into the correlation between XPA 
mutations and XP disease symptoms.  Different XPA mutations lead to different 
disease phenotypes
4,12,13,107
; complete loss, substantial truncation, and unfolding 
of the DBD are known to lead to severe XP disease phenotypes.  However, 
genotype-phenotype correlations and mechanisms behind missense mutations 
remain poorly understood
8,13,110,162,163
.  XP patients with the gene truncated to 
XPA1-210 exhibit severe neurodegeneration, whereas those with the gene truncated 
to XPA1-227 show only mild neurodegeneration
13.  My study showed that XPA98-227 
has mildly reduced and XPA98-219 has severely reduced DNA binding.  Since 
XPA1-210 is even further truncated at the C-terminus than XPA98-219, it is expected 
that this construct retains very little or no DNA binding activity.  These 
observations suggest that the loss of DNA binding activity of XPA is related to 
severe XP symptoms. 
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It is worth noting that DNA binding affinity is one of several factors that 
can contribute to biochemical malfunction of disease-associated mutations.  As in 
the case of the V166A mutation, which was found to be destabilized compared to 
the WT protein, an effect on function may arise not only DNA binding, but also 
protein interactions and cellular turnover.  For example, although the R207Q 
mutation has significantly weakened DNA binding affinity, the corresponding 
R207E mutant is capable of the repair of UV lesions in a host reactivation assay
65
.  
The assay is not sensitive to effects on the rate of repair, which may be 
compromised when DNA binding affinity is diminished.  Moreover, this residue 
is also important for interactions with the NER factor XPE
48
.  Clearly, multiple 
factors have the potential to lead to XP disease in the case of R207Q.  
 
A structural model for the NER complex 
As the initial steps in characterizing how NER complex is organized, we 
began to investigate the overall architecture of the full length XPA-DNA-RPA 
complex by SAXS.  For multi-domain proteins and protein complexes, 
interpretation of SAXS data is greatly facilitated by high resolution structures or 
models of the components.  High resolution models and NMR titration data are 
available to model XPA-DNA interaction in atomic detail.  While structures were 
available for individual proteins, information on the interaction between the XPA 
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globular core and RPA70AB was limited.  In order to fill this gap in knowledge, 
this work has identified the residues critical in this interaction with and without  
 
 
Figure 4.1:  Model of some XPA interactions in the NER complexes.  An 
homology model of XPA102-214 in complex with an AAF-containing duplex was 
built based on the Rad14t structure (PDB: 5A3D).  A SAXS model was used for 
the RPA DNA binding core in complex with ssDNA.  The structure of RPA70N 
is taken from an X-ray crystal structure (PDB: PDB: 1EWI structure).  The 
structure of RPA32C in complex with a peptide fragment of UNG2 (PDB: 1DPU) 
was used to represent RPA32C bound to XPA29-46.  The XPF-ERCC1 model 
combined ERCC196-214 in complex with XPA67-80, XPF842-916 in complex with 
ssDNA (PDB: 2KN7), and ERCC1220-297 (PDB: 1Z00).  Dashed lines indicate 
potential path of linkers or DNA.  The DNA lesion is represented by a red star.  
Colors: XPA – pink, RPA70 – blue, RPA32 – green, RPA14 – dark red, XPF – 
purple, ERCC1 – violet, DNA – dark grey. 
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the presence of ssDNA.  Figure 4.1 presents an initial model using available 
structural data for a NER incision complex containing XPA, RPA, and 
XPF/ERCC1, using a combination of mapped interactions between NER proteins 
and currently available structures.  A homology model of human XPA in complex 
with DNA constructed using the Rad14 structure was used for placing XPA at the 
ssDNA-dsDNA junction 3′ to the lesion.  SAXS data for the RPA DNA binding 
core bound to 30-nts of ssDNA was used to generate the model for RPA bound to 
the undamaged strand in the NER bubble
175
.  While not included in Figure 4.1 for 
clarity, further modeling can incorporate the structure of XPF-ERCC1 in complex 
with the XPA ERCC1-binding region and the structurally characterized portions 
of TFIIH and XPG
66–77,176
.  XPA interactions with XPC and DDB1-XPE 
complexes are also relevant to modeling the early stages of assembling the NER 
incision complex.  XPE interaction is especially interesting because it maps to the 
C-terminal side of the XPA DBD (residues 185-226, Figure 1.3), and most likely 
overlaps with the DNA binding site.   
While there are a number of structures and models for NER proteins, the 
current body of information is insufficient to build complex NER incision 
complexes.  Biophysical studies described in chapters 3 for characterizing the 
XPA-DNA interaction in human NER will further refine the model in 
combination with high resolution structures or computational models of XPA 
DBD in complex with appropriate DNA substrates.  Maturation of the studies 
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described in Appendix A to elucidate interactions of the XPA globular core with 
RPA70AB, as well as the characterization of the full-length XPA-DNA-RPA 
complex, would also aid in the refinement of models of the NER complex.  Since 
the NER incision complexes progressively incorporate key proteins, it is 
important to investigate the trajectory of structures of complexes over time.  Such 
an endeavor is within reach of current biophysical/structural techniques, in 
particular with the recent developments in the application of cryo-electron 
microscopy (cryo-EM) to structural analysis of multi-protein complexes.   
 
Future Directions 
XPA as a drug target 
Mechanistic understanding of XPA function has the potential to inform 
drug development.  On one hand, understanding the mechanism of action can be 
used directly to find strategies to compensate or even elevate DNA repair 
activities of patients with XP disease.  On the other, the suppression of NER has 
been increasingly recognized as a potential adjuvant therapy during treatments 
with DNA damaging agents such as radiation and cisplatin drugs
154
.  These 
treatments result in covalent adducts and DNA cross-links, lesions that are most 
commonly repaired by NER.  It has been increasingly recognized that resistance 
to treatment with DNA damaging agents arises over time due to up-regulation of 
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the DNA damage response and repair pathways.  Hence, inhibitors targeting XPA 
interfaces could potentially enhance the efficiency of treatment with DNA 
damaging agents by suppressing NER.  Unlike other XP proteins, XPA is 
understood to be a factor specific to NER and mutations of XPA are detrimental 
to NER function.  Therefore, targeting XPA could selectively inhibit NER 
function without affecting other pathways.  However, as will be discussed below, 
there is increasing realization that XPA may be involved in non-NER pathways.  
Interestingly, circadian oscillation of XPA was observed in mice liver but not in 
testis
177
.  Further investigation of tissue-specific distribution and behavior of XPA 
could contribute to potential interest in tissue-specific NER inhibitors.    
Knowledge of the structure of XPA bound to the NER bubble substrate 
and/or other NER proteins is of interest because it reveals critical sites to target 
for the development of inhibitors of NER.  3D structures are of particular interest 
because small molecule inhibitors that target interaction interfaces are efficiently 
identified by structure-based approaches.  It is important to note that increased 
efficiency of chemotherapy by combining with a NER inhibitor would result in 
increased toxicity.  Therefore, knowledge of differences in XPA expression levels 
and function in cancer and normal cells may be useful for selectively targeting 
cancer cells.  
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Potential involvement of XPA in other pathways 
 Currently, there is no clear evidence that XPA could play a role in 
pathways other than NER.  However, there are several reports showing the 
interaction of XPA with non-NER proteins
92,103,104,177
.  As mentioned in Chapter 3, 
recently reported structures of yeast XPA in complex with DNA may represent a 
DNA binding mode of XPA that is operative outside of NER.  While dimerization 
of XPA was observed in vitro
57
, our data together with current structural results 
suggest XPA does not form a dimer within NER complexes.  These observations 
suggest that XPA may be involved in DNA processing pathways other than NER.  
One approach to test this possibility is the flow-cytometric host cell reactivation 
assay (FM-HCR)
178
.  FM-HCR allows for high-throughput investigation of the 
involvement of certain protein in different DNA repair pathways.  To this end, our 
group is planning collaboration with Dr. Zachary Nagel at Harvard, who has 
developed the FM-HCR approach.  
 
Organization and remodeling of the NER complex 
Even though a significant amount of biochemical, genetic, and functional 
data has been accumulated on XPA and other NER proteins, a dearth of structural 
information has limited progress towards understanding how XPA, and eukaryotic 
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NER in general, actually works.  Because XPA has a central role in NER through 
its network of protein and DNA interactions, to fully understand the function of 
XPA it is necessary to study it in the context of NER incision complexes.  
Determining structures of full-length XPA and of complexes with DNA and 
fragments of its partner proteins will be useful steps, but ultimately complete 
understanding of function requires structures of full complexes.  The most 
significant challenge in these pursuits is the preparation of the complexes.  
Although in vitro NER has been achieved via reconstitution of purified 
components
3
, much higher quantities are required for structural analyses and so 
production techniques must be optimized.  One promising direction is the 
development of new types of expression systems for the production of protein 
complexes.  These include new highly modularized polycistronic and 
polypromoter approaches, and high yield insect and mammalian cell culture 
technologies
179,180
. 
Advances in the past ~10 years in techniques for structure determination 
have set the stage for comprehensive studies of complex multi-domain proteins 
like XPA, and of multi-protein complexes like the NER incision complexes.  X-
ray crystallography in particular has realized a number of key developments 
including the shift to robotic systems for crystal screening, increased automation 
at synchrotron beamlines, and the availability of microfocus beamlines and 
FELs
181–183
.  In addition, exciting recent advances in cryo-EM through the 
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development of direct electron detectors, fast data acquisition, and protocols for 
tracking particle movement during data acquisition, are poised to revolutionize 
structural biology of NER incision complexes.  Equally important developments 
have been made in recognizing that structural snapshots are insufficient to 
understand the function of multi-protein complexes; the complexes are not static 
but rather dynamic assemblies, and even the constituent multi-domain proteins are 
intrinsically dynamic and constantly remodeling their architecture.  This critical 
advance in understanding dynamic proteins and complexes has been driven by 
applications of small angle scattering (in particular with X-rays, SAXS) and NMR 
spectroscopy in combination with computational modeling. 
 
Concluding Remarks 
 The studies presented here offer insights into the molecular basis of XPA 
interactions in human NER.  We updated the DNA binding construct of XPA, 
which was misidentified about 20 years ago.  Key residues involved in DNA and 
RPA70 interactions, as well as initial insights into structural organization of XPA-
RPA-DNA complex in NER were also demonstrated.  We also cataloged disease-
associated XPA mutations and showed initial steps in dissecting the molecular 
basis for XP symptoms correlated to each mutation.  These findings serve as 
stepping stones in elucidating the molecular details of human NER pathway, 
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which could then contribute to development of treatments for XP disorders as well 
as cancer therapeutics.   
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APPENDIX 
 
INTERACTIONS OF XPA AND RPA 
 
A. INTERACTIONS OF THE GLOBULAR CORE OF XPA AND RPA70AB 
 
Introduction 
XPA and RPA work together as the central scaffold in human NER.  
While new data on XPA-DNA interaction have been reported, the current body of 
information and structures are not sufficient to understand how human XPA 
interacts with the NER bubble.  Since XPA DBD contains DNA and RPA70 
interaction residues (Figure 1.3), it is possible that these two interactions are 
coupled.  However, the interaction of XPA with RPA70AB is poorly 
characterized, in part because there are conflicting reports for where RPA70AB 
binds within XPA from indirect methods.  An early NMR titration of XPA98-219 
with RPA70 truncation constructs suggested the zinc finger in the N-terminus of 
XPA98-219 is involved
39,45
.  On the other hand, biochemical pull-down and cell-free 
NER assays with XPA mutants concluded that C-terminal residues of XPA98-219, 
overlapping with the DNA binding residues described in chapters 2 and 3, are 
responsible for the interaction
89,90
. 
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In my studies using NMR titrations, we confirmed that the N-terminal 
region of the XPA globular core is responsible for RPA70AB binding.  We found 
that XPA and ssDNA elicit chemical shift perturbations of some common 
residues of RPA70AB, but they do not compete for the same binding site.  In 
combination with available high resolution structures, these data will be used to 
build structural models for XPA globular core-DNA-RPA70AB complex. 
 
Results and Discussion 
 A series of NMR titration experiments were performed in order to fill in 
the gap in knowledge regarding how XPA interacts with RPA70AB.  An initial 
titration of 
15
N-labeled XPA DBD with RPA70AB showed significant exchange 
broadening of resonances of residues in the N-terminal zinc finger region of XPA 
DBD (Figure A.1).  This data suggests that there are separate binding sites for 
DNA and RPA70AB on the XPA globular core (Figure 3.6).  Importantly, this 
initial experiment revealed that XPA DBD is less soluble at lower salt 
concentration buffers, and is unable to be concentrated to an appropriate range to 
fully characterize its weak binding to RPA70AB.  Since the C-terminal extension 
required for DNA binding was not involved in RPA70AB interaction, further 
NMR studies were performed using more soluble XPA98-219 construct.  Titration 
of 
15
N-RPA70AB and unlabeled XPA98-219 induced broadening of residues that 
overlap with the ssDNA binding site of RPA70AB (Figure A.2).  In order to 
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determine if there is competition between ssDNA and XPA globular core on 
RPA70AB binding site, a follow up titration was performed in the presence of 
ssDNA.  These data indicate that the XPA globular core, RPA70AB, and ssDNA 
form a ternary complex with independent binding sites (Figure A.3).  Importantly, 
together the experiments identified residues involved in the XPA-RPA70AB 
interaction, which will allow the creation of a model of the complex.  
 Initial sets of XPA mutations to disrupt each of the two RPA binding 
residues were designed and will be created in both FL and DBD constructs.  We 
plan to collaborate on functional analysis of these mutations with Dr. Orlando 
Schärer at Cold Spring Harbor and Dr. Zachary Nagel at Harvard.  Mutant FL 
protein cDNA will be sent to their laboratories so that these mutations can be 
tested for their effect on NER efficiency or recruitment of downstream NER 
factors in cellular studies at the Schärer lab, and possible involvement in other 
DNA repair pathways in the Nagel lab.   
 
Materials and Methods 
Protein Production 
Recombinant expression plasmids for pBG100 XPA98-219, XPA98-239 were 
described previously
53
.  pSV281 RPA70AB (RPA70181-422) was constructed and 
made available by L. S. Mizoue, Center for Structural Biology, Vanderbilt 
University.  All constructs contain N-terminal 6xHis tag cleavable by H3C (for 
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pBG100 plasmids) or TEV (for pSV281 plasmid) proteases.  All proteins were 
purified as described previously
53
. Purification of RPA70AB followed the same 
protocol as XPA constructs with the exception of the use of different proteases for 
His-tag cleavage. 
 
DNA Substrate 
Desalted 8-mer ssDNA (dC8) substrates were purchased from Sigma-
Agldrich Co. (St. Louis, MO).  dC8 were dissolved in the NER buffer (see below) 
to the stock concentration of 1 mM. 
 
NMR Titrations 
All samples for DNA titrations were concentrated to 50 - 300 µM in the 
NMR buffer containing 20 mM Tris, pH 7.0, 75 mM KCl, 1 mM Tris(2-
carboxymethil) phosphine (TCEP), and 5 % 
2
H2O.  Titrations were performed at 
25 °C using a Bruker AVANCE 900 MHz spectrometer equipped with a cryoprobe 
following the procedure described previously
53
.  Titration with the presence of 
dC8 were performed by first collecting 
15
N-
1
H TROSY-HSQC of labeled protein, 
add 1 equimolar amount of DNA and take another spectrum, followed by the 
addition of unlabeled protein and the third data collection.  Titration data were 
analyzed using available backbone resonance assignment of XPA98-219 (BMRB 
4249), XPA98-239 (chapter III), or RPA70AB
122
. 
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Figure A.1: NMR titration of 
15
N XPA DBD with RPA70AB.  Left - overlay of 
the 900 MHz 
15
N-
1
H TROSY-HSQC spectrum of XPA DBD in the presence (red) 
and absence (black) of unlabeled RPA70AB.  Spectra were acquired in a buffer 
containing 20 mM Tris, pH 7.0, 75 mM KCl, 1 mM Tris(2-carboxymethil) 
phosphine (TCEP), and 5 % 
2
H2O at 25 °C.  Right - CSPs from spectra shown in 
the left panel mapped on the 1XPA structure. 
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Figure A.2: NMR titration of 
15
N RPA70AB with XPA98-219.  Left - overlay of 
the 900 MHz 
15
N-
1
H TROSY-HSQC spectrum of RPA70AB in the presence (red) 
and absence (black) of unlabeled XPA98-219.  Spectra were acquired in a buffer 
containing 20 mM Tris, pH 7.0, 75 mM KCl, 1 mM Tris(2-carboxymethil) 
phosphine (TCEP), and 5 % 
2
H2O at 25 °C.  Right - CSPs from spectra shown in 
the left panel mapped on the 1JMC structure. 
 
 
 
 
Figure A.3: NMR titration of 
15
N RPA70AB with XPA98-219 in the presence of 
ssDNA.  Three orientations of 1JMC structures indicating CSPs induced by the 
addition of ssDNA (purple), and the addition of XPA98-219 to the pre-formed 
RPA70AB-DNA complex (red).  DNA molecule in the 1JMC structure is 
highlighted in green. 
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B. TOWARDS STRUCTURAL ANALYSIS OF THE XPA-RPA COMPLEX  
 
Introduction 
 Previous work from the lab defined the molecular basis of the first contact 
point between XPA and RPA (N-terminus of XPA and RPA32C domain).  
Together with the new data reported here, we now have the complete map of 
XPA-RPA interaction residues.  As a first step towards elucidating structures of 
the NER complex, structural investigation of full-length XPA-DNA-RPA 
complexes is critical.  XPA and RPA are the two scaffolding proteins in human 
NER where each protein interacts with the NER bubble to organize the substrate.  
Initial SAXS analysis of XPA-DNA-RPA was conducted.  However, 
interpretation of SAXS data for multi-domain proteins and protein complexes 
relies on high resolution structures or models of the components.  Construction of 
high resolution structural model of the ternary complex of XPA globular core, 
ssDNA and RPA70AB is ongoing using the information obtained from this 
section and the resulting structural model will be a critical piece in interpreting 
the full-length ternary complexes. 
 
Sample Design and Preparation 
This section summarizes the preliminary results from the two sets of data 
collected on December 2015 at SSRL beamline and March 2016 at the SIBYLS 
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beamline as well as insights for the future experiments and interpretation of these 
results. 
 
From December/ SSRL  
1. XPA98-239  
2. XPA98-239 + DNA  
3. XPA98-239 + DNA + RPA70AB  
4. XPA 
5. XPA + DNA + RPA  
 
From March/ SIBYLS 
1. XPA98-239 
2. XPA98-239 + DNA 
3. XPA98-239 + DNA + RPA70AB 
4. XPA + DNA 
5. XPA + DNA + RPA 
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All samples were prepared in identical buffer (50 mM HEPES pH 8.5, 75 
mM KCl, 10 % glycerol, 1 mM DTT).  All samples were run through size-
exclusion column prior to data collection.  Samples were further concentrated 
when needed (SIBYLS recommends sample concentrations over 1 mg/ml).  For 
each sample, 3 different concentrations (ideally, the concentration right off the 
sizing column and 2 serial dilutions of that concentration) and blank(s) were 
prepared.  One blank was provided for SSRL samples and two for SIBYLS.  To 
ensure the identity of blank to the sample buffer, first fractions from size-
exclusion chromatography were used as blank for each sample.  Samples 
containing FL proteins were provided with quite low concentrations and required 
concentration prior to data collection.  Low concentrations of these samples could 
have been due to availability of the components.  However, to avoid aggregations, 
it should be avoided in the future by running concentrated samples over the 
column.   
While 8/12 5′ overhang (Figure A.4-B) was used for the first SAXS 
samples 2 and 3 sent on mid-December due to availability, I used a DNA 
construct similar to those used for FL complex in March (Figure A.4-C).  The 
asymmetric Y-shaped junction for the FL complex has 7 nt duplex, 25 nt top 
overhang and 8 nt bottom overhang (Figure A.4-A).  For samples 2 and 3 
prepared on March, I used the same sequence but trimmed the top strand to 10 nt 
for RPA70AB binding (based on crystal structure of RPA70AB + ssDNA 
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complex, PDB: 1JMC, which contains 8 nt ssDNA) and bottom strand to 4 nt 
(Figure A.4-C).  This DNA bound well to XPA98-239 as expected, however, when 
XPA98-239 + DNA complex was mixed with RPA70AB and run over s75 column, 
they didn't elute together (although there was overlap and I sent out overlapped 
parts to SAXS, Figure A.4-E).  This separation was not observed for SSRL 
sample (Figure A.4-D) when similar but different DNA substrate was used.  
 
Data Analysis 
This section lists brief description of how the data was analyzed, SAXS 
parameters for each sample, and implications of these data.  In general, data 
collected at SIBYLS had higher quality than those from SSRL.  Each buffer and 3 
concentrations of samples were scanned 10 times at SSRL and 32 times at 
SIBYLS.  After data collection, they provided buffer subtracted intensity data.  
For SIBYLS data, 3 types of buffer subtracted data were provided – subtraction of 
first buffer, second buffer, average of the two.  SIBYLS also provided a 
spreadsheet describing which type of buffer subtraction is most appropriate for 
further analysis along with other notes from data collection.  SSRL also provided 
averaged data from 10 scans for each sample at each of the 3 concentrations. 
All SAXS data were analyzed using SCATTER. 
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SSRL Data from December 2015 
1. XPA98-239 
Due to low data quality, I was not able to obtain reasonable P(r) curve and 
analysis was aborted. Concentration dependence was observed for Rg values 
which could be due to aggregation.  However, signal was quite weak for lowest 
concentration of 0.5 mg/ml.  Figure A.5 summarizes parameters obtained for this 
sample.  As indicated by the first plateau in Kratky-Debye plot in flexibility plots 
and low Porod exponent, the sample is flexible as expected.   
 
2. XPA98-239 + DNA  
Figure A.6 summarizes parameters obtained for this sample.  
Concentration dependence was also observed for Rg values but signal was better 
at higher concentrations.  While still flexible, Porod exponent was slightly higher 
than sample 1.  This indicates that XPA DBD becomes less flexible upon binding 
to DNA.  However, as shown in Figure A.4, DNA substrate was designed to 
accommodate RPA70AB binding and without this molecule, the ssDNA chain 
that’s not bound to XPA DBD can provide flexibility, although the contribution 
would be minor due to the small size.  C-terminus of XPA is also expected to be 
flexible.    
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As indicated in Figure A.6, P(r) analysis didn’t go well due to poor fit to 
the data.  This gave Dmax value of 72 Å which could be possible considering 
estimated Dmax value of ~ 60 Å from the structure of the globular core of XPA 
(PDB: 1XPA).  Ab initio shape calculation was performed using DAMMIF 
(Figure A.7).  While we can’t trust these shapes too much due to the low Porod 
exponent, 7 calculated shapes showed common elongated features.  Comparing 
shapes 2, 3, and 5 with 1XPA structure, the structure could fit into the bottom part 
of these shapes and the extra tail on the top could be attributed to C-terminal 
extension of the protein and/or the ssDNA overhang of the substrate. 
 
3. XPA98-239 + DNA + RPA70AB  
Figure A.8 summarizes parameters obtained for this sample.  Highest 
concentration had aggregation as shown from Gunier region of the intensity plot.  
Rg values were again concentration dependent.  Porod exponent was higher than 
samples 2, indicating RPA70AB binding to ssDNA (and XPA) makes the 
complex more globular.  As noted in pink in Figure A.8, P(r) analysis was tricky.  
Dmax value of 66 is reported here but when higher value was applied, there was 
better agreement between real and reciprocal Rg and I(0) values.  However, at 
higher Rg, P(r) curve gave strange features.  Figure A.9 compares calculated ab 
initio shapes and a model of this complex composed of available structures at 
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PDB and my NMR titrations.  While Porod exponent is still not high enough to 
fully rely on these shapes, most calculated shapes has common diamond shapes 
and are similar in size with the model structure. 
 
4. XPA 
Figure A.10 summarizes parameters obtained for this sample.  
Concentration dependence was observed for Rg values.  Smiling was observed for 
all intensity plots during Gunier analysis.  Due to low data quality, I was not able 
to obtain reasonable P(r) curve and analysis was aborted.  As indicated by the first 
plateau in Kratky-Debye plot in flexibility plots and low Porod exponent, the 
sample is flexible as expected.   
 
5. XPA + DNA + RPA  
Figure A.11 summarizes parameters obtained for this sample.  As evident 
from the intensity plots, signals were quite weak for all samples most likely due to 
low concentrations.  They also seem to be aggregated as smiling was observed 
from Gunier analysis. 
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SIBYLS Data from March 2016 
 
The data collected at SIBYLS had higher quality than those from SSRL.  
As mentioned above, each sample was scanned for 32 times and averaging was 
done manually using AdjustTwoRegions.py.  
 
1. XPA98-239 
Figure A.12 summarizes parameters obtained for this sample.  Only 
highest concentration data was used for analysis because lowest concentration had 
bubble and medium concentration was aggregated.  Flexibility plots and Porod 
exponent show the sample is flexible as expected.  P(r) curve was asymmetric and 
had a feature at long distance which is most likely due to flexibility of the C-
terminal residues.  Main peak from P(r) lands around ~70 Å which is close to 
expected Dmax of the globular core of XPA (determined from 1XPA structure 
containing residues 98 – 210).  All 13 ab initio shapes look elongated (Figure 
A.13).   
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2. XPA98-239 + DNA 
Figure A.14 summarizes parameters obtained for this sample.  Like SSRL 
samples, slight increase in Porod exponent was observed compared to sample 1 
indicating that DNA binding reduces flexibility of XPA DBD.  This is also 
observed from the change in the shape of P(r) curve between Figures A.12 and 
A.14.  The extra feature at high Dmax shrunk upon DNA addition.  There is still 
small tail in this region but as discussed in SSRL sample 2 section, this is most 
likely due to extra ssDNA in the substrate to accommodate RPA70AB which is 
not present in this sample. 
Calculated ab initio shapes for this sample (Figure A.14) look less flexible 
compared to XPA DBD by itself (Figure A.12).  However, in both cases, the 
envelopes look much bigger than 1XPA structure.   
 
3. XPA98-239 + DNA + RPA70AB 
As noted in Samples section, separation of XPA DBD and RPA70AB was 
observed during preparation (Figure A.4).  Therefore, this data set may not 
represent that of homogeneous ternary complex.  Figure A.15 summarizes 
parameters obtained for this sample.  Porod exponent of 3.5 was obtained and this 
is highest of all samples analyzed here.  As noted in Figure A.15 in pink, P(r) 
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curve shows feature at high Dmax, which could be due to flexible DNA 
extensions.  Ab initio shapes for this sample (Figure A.16) look more rigid 
compared to Figures A.13 and A.14 and the envelopes are similar in size with the 
model structure.  Interestingly, Dmax obtained for this sample was almost 2-fold 
bigger than the comparable sample sent to SSRL.  This could be due to the 
difference in DNA substrate and the separation problem encountered when this 
sample was prepared.  I’m suspecting this sample may be just RPA70AB bound 
to DNA. 
  
4. XPA + DNA  
Figure A.18 summarizes parameters obtained for this sample.  As noted in 
Samples section, this sample was provided with very low concentration and 
required significant concentration.  Due to low sample quality, I was not able to 
complete P(r) analysis for this sample. 
 
5. XPA + DNA + RPA 
Figure A.19 summarizes parameters obtained for this sample.  Although 
sample concentrations were quite low, medium and high concentration samples 
had reasonable signal due to the size of the complex.  This sample appeared to be 
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highly flexible with the Porod exponent of 2.1.  This is expected from the 
flexibility arising from N- and C-terminus of XPA as well as the linkers between 
RPA.  During first analysis, I obtained Dmax above 200 Å.  However, this value 
gave strange feature in P(r) curve as seen in Figure A.16.  Therefore, I repeated 
P(r) analysis with lower Dmax of 190 Å and more reasonable curve was obtained.  
Main peak in this curve lands around 120 Å and other features are observed 
beyond this point. 
Ab initio shapes were also calculated for this sample (Figure A.20).  As 
expected, these shapes are much bigger compared to those from XPA DBD 
complexes. 
 
Conclusion 
Although data introduced here are preliminary, these initial data collection 
and analysis revealed hints to improve future SAXS analysis of XPA complexes.  
For the initial analysis, the goal was to see how XPA-DNA-RPA complex looks 
like.  For this reason, samples with truncated proteins were designed to resemble 
the condition from FL complex.  However, it sometimes caused problems 
interpreting the data by creating extra flexibility (as in the case for sample 2) or 
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prevented complex formation due to different DNA substrate design (sample 3).  
Below is the list of things to consider for future SAXS analysis. 
1. Data qualities were higher for those collected at SIBYLS than SSRL. 
2. It would be interesting to compare XPA98-219 with XPA98-239. 
3. For sample 2 (XPA98-239 + DNA), DNA substrate with shorter ssDNA 
overhang should be used to avoid flapping of nucleotides not engaged in XPA 
binding.  From my previous DNA substrate screening, 8/4 5′ overhang 
substrate (8 nt duplex and 4 nt ssDNA overhang) had sufficient affinity to 
XPA DBD.  
4. For sample 3 (XPA98-239 + DNA + RPA70AB), DNA substrate with single 
overhang and not double overhang should be used to ensure complex 
formation.   
5. In order to avoid aggregation problems, running sizing column just before 
SAXS analysis should be considered. 
6. Sample 4 and 5 are very flexible systems.  Since we know that RPA70N 
doesn’t interact with XPA nor DNA, a complex with FL-XPA + DNA + and 
RPA construct without 70N should also be analyzed for comparison.  C-
terminal of XPA beyond residue 239 is not engaged in DNA nor RPA 
interaction so XPA1-239 would be a better construct for SAXS analysis. 
7. For the analysis of sample 5 (XPA-DNA-RPA) comparisons with Dr. Chris 
Brosey’s SAXS data on RPA DBC with ssDNA is required. 
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8. For both samples 3 and 5, different junction DNA substrates should be tested. 
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Figure A.4: DNA Substrates and SDS-Page gel for Sample 3. DNA substrates used for 
samples 5 and 4 (A, no DNA for sample 4 for SSRL), samples 2 and 3 for SSRL (B), and for 
SIBYLS (C). Pink indicates identical sequence. SDS-Page gel from size-exclusion 
purification of sample 3 for SSRL (D) and SIBYLS (E). Pink box indicate fractions pooled 
for SAXS analysis. 
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Figure A.5: Summary of SAXS analysis of XPA98-239 from SSRL. Table on the 
top lists sample ID, concentrations, data used for further analysis are indicated. 
‘Start’ and ‘End’ columns indicate the range of data points used for analysis, if 
merged data was created for further analysis, the range of merged curves are 
indicated in parenthesis. Real and reciprocal I(0) and Rg as well as Dmax values 
are indicated if available. Below the table, intensity plots, Kracky plot, plots for 
flexibility and Porod analysis are also shown. P(r) curve as well as fit of 
calculated data to the low data are also shown if available. 
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Figure A.6: Summary of SAXS analysis of XPA98-239 + DNA from SSRL. 
Table on the top lists sample ID, concentrations, data used for further analysis are 
indicated. ‘Start’ and ‘End’ columns indicate the range of data points used for 
analysis, if merged data was created for further analysis, the range of merged 
curves are indicated in parenthesis. Real and reciprocal I(0) and Rg as well as 
Dmax values are indicated if available. Below the table, intensity plots, Kracky 
plot, plots for flexibility and Porod analysis are also shown. P(r) curve as well as 
fit of calculated data to the low data are also shown if available. 
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Figure A.7: Ab initio shape calculations for XPA98-239 + DNA from SSRL. 
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Figure A.8: Summary of SAXS analysis of XPA98-239 + DNA + RPA70AB 
from SSRL. Table on the top lists sample ID, concentrations, data used for 
further analysis are indicated. ‘Start’ and ‘End’ columns indicate the range of data 
points used for analysis, if merged data was created for further analysis, the range 
of merged curves are indicated in parenthesis. Real and reciprocal I(0) and Rg as 
well as Dmax values are indicated if available. Below the table, intensity plots, 
Kracky plot, plots for flexibility and Porod analysis are also shown. P(r) curve as 
well as fit of calculated data to the low data are also shown if available. 
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Figure A.9: Ab initio shape calculations for XPA98-239 + DNA + RPA70AB 
from SSRL. 
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Figure A.10: Summary of SAXS analysis of XPA from SSRL. Table on the top 
lists sample ID, concentrations, data used for further analysis are indicated. ‘Start’ 
and ‘End’ columns indicate the range of data points used for analysis, if merged 
data was created for further analysis, the range of merged curves are indicated in 
parenthesis. Real and reciprocal I(0) and Rg as well as Dmax values are indicated 
if available. Below the table, intensity plots, Kracky plot, plots for flexibility and 
Porod analysis are also shown. P(r) curve as well as fit of calculated data to the 
low data are also shown if available. 
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Figure A.11: Summary of SAXS analysis of XPA + DNA + RPA from SSRL. 
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Figure A.12: Summary of SAXS analysis of XPA98-239 from SIBYLS. Table on 
the top lists sample ID, concentrations, data used for further analysis are indicated. 
‘Start’ and ‘End’ columns indicate the range of data points used for analysis, if 
merged data was created for further analysis, the range of merged curves are 
indicated in parenthesis. Real and reciprocal I(0) and Rg as well as Dmax values 
are indicated if available. Below the table, intensity plots, Kracky plot, plots for 
flexibility and Porod analysis are also shown. P(r) curve as well as fit of 
calculated data to the low data are also shown if available. 
 
 
 
 
 
 
140 
 
 
Figure A.13: Ab initio shape calculations for XPA98-239 from SIBYLS. 
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Figure A.14: Summary of SAXS analysis of XPA98-239 + DNA from SIBYLS. 
Table on the top lists sample ID, concentrations, data used for further analysis are 
indicated. ‘Start’ and ‘End’ columns indicate the range of data points used for 
analysis, if merged data was created for further analysis, the range of merged 
curves are indicated in parenthesis. Real and reciprocal I(0) and Rg as well as 
Dmax values are indicated if available. Below the table, intensity plots, Kracky 
plot, plots for flexibility and Porod analysis are also shown. P(r) curve as well as 
fit of calculated data to the low data are also shown if available. 
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Figure A.15: Ab initio shape calculations for XPA98-239 + DNA from SIBYLS. 
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Figure A.16: Summary of SAXS analysis of XPA98-239 + DNA + RPA70AB 
from SIBYLS. Table on the top lists sample ID, concentrations, data used for 
further analysis are indicated. ‘Start’ and ‘End’ columns indicate the range of data 
points used for analysis, if merged data was created for further analysis, the range 
of merged curves are indicated in parenthesis. Real and reciprocal I(0) and Rg as 
well as Dmax values are indicated if available. Below the table, intensity plots, 
Kracky plot, plots for flexibility and Porod analysis are also shown. P(r) curve as 
well as fit of calculated data to the low data are also shown if available. 
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Figure A.17: Ab initio shape calculations for XPA98-239 + DNA + RPA70AB 
from SIBYLS. 
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Figure A.18: Summary of SAXS analysis of XPA + DNA from SIBYLS. Table 
on the top lists sample ID, concentrations, data used for further analysis are 
indicated. ‘Start’ and ‘End’ columns indicate the range of data points used for 
analysis, if merged data was created for further analysis, the range of merged 
curves are indicated in parenthesis. Real and reciprocal I(0) and Rg as well as 
Dmax values are indicated if available. Below the table, intensity plots, Kracky 
plot, plots for flexibility and Porod analysis are also shown. P(r) curve as well as 
fit of calculated data to the low data are also shown if available. 
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Figure A.19: Summary of SAXS analysis of XPA + DNA + RPA from 
SIBYLS. Table on the top lists sample ID, concentrations, data used for further 
analysis are indicated. ‘Start’ and ‘End’ columns indicate the range of data points 
used for analysis, if merged data was created for further analysis, the range of 
merged curves are indicated. Real and reciprocal I(0) and Rg as well as Dmax 
values are indicated if available. Below the table, intensity plots, Kracky plot, 
plots for flexibility and Porod analysis are also shown. P(r) curve as well as fit of 
calculated data to the low data are also shown if available. 
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Figure A.20: Ab initio shape calculations for XPA + DNA + RPA from 
SIBYLS. 
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